09/316624
********** STN Columbus **********

FILE 'HOME' ENTERED AT 10:03:27 ON 30 MAR 2000

=> index bioscience patents
72 FILES IN THE FILE LIST IN STNINDEX
=> s (reticulose or product (w) "r") and (rheumatoid or RA)

1 FILE CAPLUS
16 FILES SEARCHED...
24 FILES SEARCHED...
1 FILE FROSTI
37 FILES SEARCHED...
2 FILE IFIPAT
5 FILE MEDLINE
1 FILE PHIN
12 FILE PROMT
128 FILE USPATFULL
55 FILES SEARCHED...
13 FILE EUROPATFULL
66 FILES SEARCHED...

8 FILES HAVE ONE OR MORE ANSWERS, 72 FILES SEARCHED IN STNINDEX

L1 QUE (RETICULOSE OR PRODUCT (W) "R") AND (RHEUMATOID OR RA)

=> file medline caplus frosti ifipat phin promt europatfull

COST IN U.S. DOLLARS	ENTRY	SINCE FILE SESSION	TOTAL
FULL ESTIMATED COST		2.25	2.40

FILE 'MEDLINE' ENTERED AT 10:06:59 ON 30 MAR 2000
FILE 'CAPLUS' ENTERED AT 10:06:59 ON 30 MAR 2000
FILE 'FROSTI' ENTERED AT 10:06:59 ON 30 MAR 2000
FILE 'IFIPAT' ENTERED AT 10:06:59 ON 30 MAR 2000
FILE 'PHIN' ENTERED AT 10:06:59 ON 30 MAR 2000
FILE 'PROMT' ENTERED AT 10:06:59 ON 30 MAR 2000
FILE 'EUROPATFULL' ENTERED AT 10:06:59 ON 30 MAR 2000
=> s l1; dup rem l2
L2 35 L1
L3 35 DUP REM L2 (0 DUPLICATES REMOVED)

=> d 1-35 bib ab

L3 ANSWER 1 OF 35 PROMT COPYRIGHT 2000 Gale Group

AN 2000:190740 PROMT
TI Corporate Profile for Advanced Viral Research Corp.
SO Business Wire, (16 Mar 2000) pp. 1218.
PB Business Wire
DT Newsletter
LA English
WC 979
FULL TEXT IS AVAILABLE IN THE ALL FORMAT
AB Business & Medical/Health Editors
THIS IS THE FULL TEXT: COPYRIGHT 2000 Business Wire

L3 ANSWER 2 OF 35 PROMT COPYRIGHT 2000 Gale Group

AN 2000:124236 PROMT
TI Advanced Viral Research Corp. Receives Approval in Argentina for Human Clinical Studies With Antiviral &uot;Substance R&uot;.
SO Business Wire, (18 Feb 2000) pp. 125.
PB Business Wire
DT Newsletter
LA English
WC 618
FULL TEXT IS AVAILABLE IN THE ALL FORMAT
AB Health/Medical &Biotechnology Writers
THIS IS THE FULL TEXT: COPYRIGHT 2000 Business Wire

L3 ANSWER 3 OF 35 PROMT COPYRIGHT 2000 Gale Group

AN 1999:595616 PROMT
TI Oxford GlycoSciences Reports 1999 Interim Results.
SO PR Newswire, (15 Sep 1999) pp. 7794.
PB PR Newswire Association, Inc.
DT Newsletter
LA English
WC 2364
FULL TEXT IS AVAILABLE IN THE ALL FORMAT
AB - Announces Good News on Proteome Collaborations -
THIS IS THE FULL TEXT: COPYRIGHT 1999 PR Newswire Association, Inc.

L3 ANSWER 4 OF 35 PROMT COPYRIGHT 2000 Gale Group

AN 1999:497177 PROMT
TI Advanced Viral Research Corp. Announces Private Placement with Focus Investors LLC.
SO Business Wire, (5 Aug 1999) pp. 1280.
PB Business Wire
DT Newsletter
LA English
WC 305
FULL TEXT IS AVAILABLE IN THE ALL FORMAT
AB YONKERS, N.Y.--(BUSINESS WIRE)--Aug. 5, 1999--
THIS IS THE FULL TEXT: COPYRIGHT 1999 Business Wire

L3 ANSWER 5 OF 35 PROMT COPYRIGHT 2000 Gale Group

AN 1999:68088 PROMT
TI Manufacturers Alphabetic Listings.(Directory)
SO Air Conditioning, Heating & Refrigeration News, (4 Jan 1999) Vol. 206, No. 1, pp. 38(1).
ISSN: 0002-2276.
PB Business News Publishing Company
DT Newsletter
LA English
WC 84481
FULL TEXT IS AVAILABLE IN THE ALL FORMAT
AB A
THIS IS THE FULL TEXT: COPYRIGHT 1999 Business News Publishing Company

L3 ANSWER 6 OF 35 PROMT COPYRIGHT 2000 Gale Group

AN 2000:57338 PROMT
TI Manufacturers and Suppliers.(Alphabetical list of companies)
SO Lasers & Optronics, (Nov 1999) Vol. 18, No. 11, pp. S8.
ISSN: 0892-9947.
PB Cahners Publishing Company
DT Newsletter
LA English
WC 71777
FULL TEXT IS AVAILABLE IN THE ALL FORMAT
AB A
THIS IS THE FULL TEXT: COPYRIGHT 1999 Cahners Publishing Company

Subscription: $61.00 per year. Published monthly.

L3 ANSWER 7 OF 35 PROMT COPYRIGHT 2000 Gale Group

AN 1999:757959 PROMT
TI OTHER NEWS TO NOTE.
AU Antiangiogenic, Discovering The
SO BIOWORLD Today, (18 Nov 1999) Vol. 10, No. 221.
PB American Health Consultants, Inc.
DT Newsletter
LA English
WC 1682
FULL TEXT IS AVAILABLE IN THE ALL FORMAT
AB Aastrom Biosciences Inc., of Ann Arbor, Mich., was awarded a Phase I Small Business Innovation Research grant to support the development of processes for ex vivo antigen-specific T-lymphocyte production. The $100,000 six-month grant is from the National Institute of Allergy and Infectious Disease of the National Institutes of Health.
THIS IS THE FULL TEXT: COPYRIGHT 1999 American Health Consultants, Inc.

Subscription: $1350.00 per year. Published daily (5 times a week). Box 740021, Atlanta, GA 30374.

L3 ANSWER 8 OF 35 EUROPATFULL COPYRIGHT 2000 WILA

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

AN 582581 EUROPATFULL ED 19990516 EW 199918 FS PS
TIEN 1-SUBSTITUTED, 2-SUBSTITUTED 1H-IMIDAZO(4,5-C)QUINOLIN-4-AMINES.
TIDE 1,2-SUBSTITUIERTE 1H-IMIDAZO(4,5-C)CHINOLIN-4-AMINE.
TIFR 1-H-IMIDAZO(4,5-C)QUINOLIN-4-AMINES SUBSTITUEES EN POSITION 1 ET
SUBSTITUEES EN POSITION 2.
IN GERSTER, John, F., Post Office Box 33427, Saint Paul, MN 55133-3427, US;
CROOKS, Stephen, L., Post Office Box 33427, Saint Paul, MN 55133-3427, US;
LINDSTROM, Kyle, J., Post Office Box 33427, Saint Paul, MN 55133-3427, US
PA MINNESOTA MINING AND MANUFACTURING COMPANY, 3M Center, P.O. Box 33427,
St. Paul, Minnesota 55133-3427, US
PAN 300410
AG Molyneaux, Martyn William et al, c/o Ladas & Parry, 52-54 High Holborn, London WC1V 6RR, GB
AGN 34016
OS EPB1999027 EP 0582581 B1 990506
SO Wila-EPS-1999-H18-T1
DT Patent
LA Anmeldung in Englisch; Veroeffentlichung in Englisch
DS R AT; R BE; R CH; R DE; R DK; R ES; R FR; R GB; R IT; R LI; R NL; R SE
PIT EPB1 EUROPAEISCHE PATENTSCHRIFT (Internationale Anmeldung)
PI EP 582581 B1 19990506
OD 19940216
AI EP 1992-906763 19920220
PRAI US 1991-662926 19910301
US 1991-687326 19910418
RLI WO 92-US1305 920220 INTAKZ
WO 9215582 920917 INTPNR
REP EP 145340 A EP 385630 A

L3 ANSWER 9 OF 35 EUROPATFULL COPYRIGHT 2000 WILA

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

AN 577394 EUROPATFULL UP 20000305 EW 199401 FS OS STA B
TIEN Morpholine and thiomorpholine tachykinin receptor antagonists.
TIDE Morpholin und Thiomorpholin Tachykinin Rezeptorantagonisten.
TIFR Morpholine et thiomorpholine, antagonistes du recepteur de tachykinine.
IN Dorn, Conrad P., 972 Fernwood Avenue, Plainfield, NJ 07062, US;
Hale, Jeffrey J., 233 Hazel Avenue, Westfield, NJ 07090, US;
Maccoss, Malcolm, 48 Rose Court, Freehold, NJ 07728, US;
Mills, Sander G., 13A Woodbridge Terrace, Woodbridge, NJ 07095, US;
Ladduwahetty, Tamara, 185 Buckhurst Way, Buckhurst Hill, Essex IG9 6JB, GB;
Shah, Shrenik K., 25 Denise Court, Metuchen, NJ 08840, US
PA MERCK & CO. INC., 126, East Lincoln Avenue P.O. Box 2000, Rahway New
Jersey 07065-0900, US
PAN 200479
AG Quillin, Helen Kaye et al, European Patent Department, Merck & Co., Inc., Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR, GB
AGN 73841
OS ESP1994002 EP 0577394 A1 940105
SO Wila-EPZ-1994-H01-T1a
DT Patent
LA Anmeldung in Englisch; Veroeffentlichung in Englisch
DS R AT; R BE; R CH; R DE; R DK; R ES; R FR; R GB; R GR; R IE; R IT; R LI;
R LU; R NL; R PT; R SE
PIT EPA1 EUROPAEISCHE PATENTANMELDUNG
PI EP 577394 A1 19940105
OD 19940105
AI EP 1993-305086 19930629
PRAI US 1992-905976 19920629
US 1992-971448 19921104
US 1993-61914 19930519

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

AN 577394 EUROPATFULL ED 19991121 EW 199945 FS PS
TIEN Morpholine and thiomorpholine tachykinin receptor antagonists.
TIDE Morpholin und Thiomorpholin Tachykinin Rezeptorantagonisten.
TIFR Morpholine et thiomorpholine, antagonistes du recepteur de tachykinine.
IN Dorn, Conrad P., 972 Fernwood Avenue, Plainfield, NJ 07062, US;
Hale, Jeffrey J., 233 Hazel Avenue, Westfield, NJ 07090, US;
Maccoss, Malcolm, 48 Rose Court, Freehold, NJ 07728, US;
Mills, Sander G., 13A Woodbridge Terrace, Woodbridge, NJ 07095, US;
Ladduwahetty, Tamara, 185 Buckhurst Way, Buckhurst Hill, Essex IG9 6JB, GB;
Shah, Shrenik K., 25 Denise Court, Metuchen, NJ 08840, US
PA Merck & Co., Inc., 126, East Lincoln Avenue P.O. Box 2000, Rahway New Jersey 07065-0900, US
PAN 200479
AG Quillin, Helen Kaye et al., European Patent Department, Merck & Co., Inc., Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR, GB
AGN 73841
OS EPB1999062 EP 0577394 B1 991110
SO Wila-EPS-1999-H45-T1
DT Patent
LA Anmeldung in Englisch; Veroeffentlichung in Englisch
DS R AT; R BE; R CH; R DE; R DK; R ES; R FR; R GB; R GR; R IE; R IT; R LI;
R LU; R NL; R PT; R SE
PIT EPB1 EUROPAEISCHE PATENTSCHRIFT
PI EP 577394 B1 19991110
OD 19940105
AI EP 1993-305086 19930629
PRAI US 1992-905976 19920629
US 1992-971448 19921104
US 1993-61914 19930519
REP EP 436334 A EP 528495 A
FR 2534915 A
ABEN Substituted heterocycles of the general structural formula: <image> are tachykinin receptor antagonists useful in the treatment of inflammatory diseases, pain or migraine, and asthma and calcium channel blockers useful in the treatment of cardiovascular conditions such as angina, hypertension or ischemia.

L3 ANSWER 10 OF 35 EUROPATFULL COPYRIGHT 2000 WILA

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

AN 496617 EUROPATFULL ED 19991212 EW 199948 FS PS
TIEN Adenosine kinase inhibitors.
TIDE Adenosinkinaseinhibitoren.
TIFR Inhibiteurs de kinase d'adenosine.
IN Browne, Clinton E., 707 Marsopa Drive, Vista, California 92083, US;
Ugarkar, Bheemarao G., 3821 Azalea Glen, Escondido, CA 92025, US;
Mullane, Kevin M., 13814 Boquita Drive, De Mar, CA 92014, US;
Gruber, Harry E., 13083 Maritime Place, San Diego, CA 92130, US;
Bullough, David A., 13484 Ridley Road, San Diego, CA 92129, US;
Erion, Mark D., 13455 Mango Drive, Del Mar, CA 92104, US;
Castellino, Angelo, 3842 Mount Acadia Blvd, San Diego, CA 92111, US
PA Metabasis Therapeutics Inc., 9360 Towne Centre Drive, San Diego, CA 92121, US
PAN 2622511
AG Sexton, Jane Helen et al., J.A. KEMP & CO. 14 South Square Gray's Inn, London WC1R 5LX, GB
AGN 59301
OS EPB1999065 EP 0496617 B1 991201
SO Wila-EPS-1999-H48-T1
DT Patent
LA Anmeldung in Englisch; Veroeffentlichung in Englisch
DS R AT; R BE; R CH; R DE; R DK; R ES; R FR; R GB; R GR; R IT; R LI; R LU;
R MC; R NL; R PT; R SE
PIT EPB1 EUROPAEISCHE PATENTSCHRIFT
PI EP 496617 B1 19991201
OD 19920729
AI EP 1992-300580 19920123
PRAI US 1991-647117 19910123
US 1991-812916 19911223

L3 ANSWER 11 OF 35 EUROPATFULL COPYRIGHT 2000 WILA

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

AN 481000 EUROPATFULL ED 19990530 EW 199919 FS PS
TIEN RECEPTORS FOR FIBROBLAST GROWTH FACTORS.
TIDE REZEPTOREN FUeR FIBROBLASTEN-WACHSTUMSFAKTOREN.
TIFR RECEPTEURS POUR FACTEURS DE CROISSANCE DE FIBROBLASTES.
IN WILLIAMS, Lewis, T., 53 Cragmont Avenue, San Francisco, CA 94116, US;
JOHNSON, Daniel, E., 1241 Fourth Avenue, San Francisco, CA 94122, US;
LEE, Pauline, E., 10081 Rio San Diego Drive, 322, San Diego, CA 91208, US
PA THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, 300 Lakeside Drive, 22nd
Floor, Oakland, California 94612-3550, US
PAN 221072
AG Harrison, David Christopher et al, MEWBURN ELLIS York House 23 Kingsway,
London WC2B 6HP, GB
AGN 31532
OS EPB1999029 EP 0481000 B1 990512
SO Wila-EPS-1999-H19-T3
DT Patent
LA Anmeldung in Englisch; Veroeffentlichung in Englisch
DS R AT; R BE; R CH; R DE; R DK; R ES; R FR; R GB; R IT; R LI; R LU; R NL;
R SE
PIT EPB1 EUROPAEISCHE PATENTSCHRIFT (Internationale Anmeldung)
PI EP 481000 B1 19990512
OD 19920422
AI EP 1990-911235 19900706
PRAI US 1989-377003 19890706
RLI WO 90-US3830 900706 INTAKZ
WO 9100916 910124 INTPNR
REP WO 90-05522 A US 4394443 A
US 4668476 A US 4785079 A
US 4859609 A

L3 ANSWER 12 OF 35 PROMT COPYRIGHT 2000 Gale Group

AN 1999:519135 PROMT
TI SECTION 2: PRESS ACCESSORIES & SUPPLIES.
SO Printing Impressions, (July 1998) Vol. 41, No. 2, pp. 88(1).
ISSN: 0032-860X.
PB North American Publishing Company
DT Newsletter
LA English
WC 21235
FULL TEXT IS AVAILABLE IN THE ALL FORMAT
AB Blankets: Printing Press
THIS IS THE FULL TEXT: COPYRIGHT 1998 North American Publishing Company

L3 ANSWER 13 OF 35 PROMT COPYRIGHT 2000 Gale Group

AN 1999:517889 PROMT
TI Supplier Locator.
SO Appliance Manufacturer, (Dec 1998) Vol. 46, No. 12, pp. SL-1(1).
ISSN: 0003-679X.
PB Business News Publishing Company
DT Newsletter
LA English
WC 56911
FULL TEXT IS AVAILABLE IN THE ALL FORMAT
AB In this section you will find names, addresses and telephone numbers of the suppliers of the products listed in the Product Locator that follows this section. Boldface listings indicated advertisers in this issue. To obtain information about their products, circle the appropriate number on the Reader Service Card.
THIS IS THE FULL TEXT: COPYRIGHT 1998 Business News Publishing Company

L3 ANSWER 14 OF 35 EUROPATFULL COPYRIGHT 2000 WILA

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

AN 872478 EUROPATFULL ED 19981101 EW 199843 FS OS
TIEN Intermediates for the preparation of 1-substituted, 2-substituted 1H-imidazo(4,5-c)quinolin-4-amines.
TIDE Zwischenprodukte zur Herstellung von 1-substituierte, 2-substituierte-1H-Imidzao(4,5-c)Chinolin-4-Aminen.
TIFR Intermediaires pour la preparation de 4-amino-1H-imidazo(4,5-c)quinolines substituees en position 1 et 2.
IN Gerster, John F., c/o Minnesota Mining & Manu.Comp. PO Box 33427, Saint Paul, Minnesota 55133-3427, US;
Crooks, Stephen L., c/o Minnesota Mining & Manu.Comp. PO Box 33427, Saint Paul, Minnesota 55133-3427, US;
Lindstrom, Kyle J., c/o Minnesota Mining & Manu.Comp. PO Box 33427, Saint Paul, Minnesota 55133-3427, US
PA MINNESOTA MINING AND MANUFACTURING COMPANY, 3M Center, P.O. Box 33427,
St. Paul, Minnesota 55133-3427, US
PAN 300410
AG Wotherspoon, Hugh Robert, c/o Langner & Parry, 52-54 High Holborn, London WC1V 6RR, GB
AGN 83381
OS ESP1998073 EP 0872478 A2 981021
SO Wila-EPZ-1998-H43-T1a
DT Patent
LA Anmeldung in Englisch; Veroeffentlichung in Englisch
DS R AT; R BE; R CH; R DE; R DK; R ES; R FR; R GB; R IT; R LI; R NL; R SE
PIT EPA2 EUROPAEISCHE PATENTANMELDUNG
PI EP 872478 A2 19981021
OD 19981021
AI EP 1998-105754 19920220
PRAI US 1991-662926 19910418
US 1991-687326 19910418
RLI EP 582581 DIV
ABEN Intermediates for preparing 1-substituted, 2-substituted 1H-imidazo [4,5-c]-quinolin-4-amines of formula (I) are provided where X is selected from the group consisting of alkoxy, alkoxyalkyl, haloalkyl, hydroxyalkyl, alkylamido, amino or substituted amino wherein the substituent is alkyl, hydroxyalkyl, azido, chloro, hydroxy, 1-morpholino, 1-pyrrolidino, and alkylthio. The compounds of formula (I) function as antiviral agents, they induce biosynthesis of interferon, and they inhibit tumor formation in animal models. <image>

L3 ANSWER 15 OF 35 EUROPATFULL COPYRIGHT 2000 WILA

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

AN 859005 EUROPATFULL ED 19980830 EW 199834 FS OS
TIEN FUCOSE DERIVATIVES, DRUGS CONTAINING THE SAME AS ACTIVE INGREDIENT, AND
INTERMEDIATES FOR PRODUCING THE SAME.
TIDE FUCOSE-DERIVATE, MEDIKAMENTE, DIE DIESE ALS WIRKSTOFF ENTHALTEN, UND
ZWISCHENPRODUKTE FUeR IHRE HERSTELLUNG.
TIFR DERIVES DE LA FUCOSE, MEDICAMENTS DONT ILS FORMENT LE PRINCIPE ACTIF, ET
LEURS INTERMEDIAIRES DE FABRICATION.
IN TSUKIDA, Takahiro, 6-9-101, Tomobuchi-cho 1-chome Miyakojima-ku, Osaka-shi Osaka 534, JP;
KIYOI, Takao, 2-5, Hanjo 1-chome, Mino-shi Osaka 562, JP;
ACHIHA, Toshio, 296-28, Kasuga Taishi-cho Minamikawachi-gun, Osaka 583, JP;
MORIYAMA, Hideki, 1-3-301, Nagayoshinagaharanishi 4-chome Hirano-ku, Osaka-shi Osaka 547, JP;
KUROKAWA, Kiriko 1-16, Shioji 2-chome, Nishinari-ku, Osaka-shi Osaka 557, JP;
OHMOTO, Hiroshi 3-23-504, Tomobuchi-cho 1-chome, Miyakojima-ku, Osaka-shi Osaka 534, JP;
NAKAMURA, Kenji, 13-11, Shin-imazato 4-chome Ikuno-ku Osaka-shi, Osaka 544, JP;
KONDO, Hirosato, 6-A-210, Satsukigaokahigashi Suita-shi, Osaka 565, JP;
WADA, Yukihisa, 6-7-405, Tomobuchi-cho 1-chome, Miyakojima-ku Osaka-shi
Osaka 534, JP;
SAITO, Tadayuki, 5-11-210, Tomobuchi-cho 1-chome Miyakojima-ku, Osaka-shi Osaka 534, JP
PA KANEBO, LTD., 17-4 Sumida 5-chome Sumida-ku, Tokyo 131, JP
PAN 202610
AG Hansen, Bernd, Dr. Dipl.-Chem. et al, Hoffmann Eitle, Patent- und Rechtsanwaelte, Arabellastrasse 4, 81925 Muenchen, DE

AGN 4924
OS ESP1998056 EP 0859005 A1 980819
SO Wila-EPZ-1998-H34-T1a
DT Patent
LA Anmeldung in Japanisch; Veroeffentlichung in Englisch; Verfahren in Englisch
DS R AT; R BE; R CH; R DE; R DK; R ES; R FI; R FR; R GB; R GR; R IE; R IT;
R LI; R LU; R MC; R NL; R PT; R SE
PIT EPA1 EUROPAEISCHE PATENTANMELDUNG (Internationale Anmeldung)
PI EP 859005 A1 19980819
OD 19980819
AI EP 1996-935412 19961023
PRAI JP 1995-303476 19951026
JP 1996-175487 19960613
JP 1996-231482 19960812
RLI WO 96-JP3081 961023 INTAKZ
WO 9715585 970501 INTPNR
ABEN A compound of the formula (I): <image> wherein X.sup1. is a group of one of the following formulae (1), (2) and (3): <image> R.sup1. is a branched long chain alkyl group, R.sup2. is .horbar.CONHR.sup3., a carboxyl group or a hydrogen atom, n is an integer of 0, 1 or 2, and R.sup3. is a lower alkyl group or a phenyl group, or a pharmaceutically acceptable salt thereof, which is useful as a selectin inhibitor, and can be used in the prophylaxis or treatment of various inflammatory diseases such as inflammatory dermatitis (e.g., atopic dermatitis, contact hypersensitivity, photodermatosis, etc.), autoimmune chronic diseases (e.g. **rheumatoid** arthritis, chronic thyroiditis, etc.), and ischemia-reperfusion injury.

L3 ANSWER 16 OF 35 EUROPATFULL COPYRIGHT 2000 WILA

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

AN 623852 EUROPATFULL UP 20000130 EW 199445 FS OS STA B
TIEN Resist compositions for circuit boards.
TIDE Resistzusammensetzungen fuer gedruckte Schaltungen.
TIFR Compositions formant reserve pour circuits imprimes.
IN Kawade, Masato, c/o Ibiden Co., Ltd., 1-1, Kitaka, Ibigawa-cho, Ibi-gun, Gifu, JP;
Asai, Motoo, c/o Ibiden Co., Ltd., 1-1, Kitaka, Ibigawa-cho, Ibi-gun, Gifu, JP
PA IBIDEN CO, LTD., 1, Kanda-cho 2-chome, Ogaki-shi Gifu 503, JP
PAN 473321
AG Patentanwaelte Gruenecker, Kinkeldey, Stockmair & Partner, Maximilianstrasse 58, D-80538 Muenchen, DE
AGN 100721
OS ESP1994079 EP 0623852 A1 941109
SO Wila-EPZ-1994-H45-T2a
DT Patent
LA Anmeldung in Englisch; Veroeffentlichung in Englisch
DS R DE; R GB; R NL
PIT EPA1 EUROPAEISCHE PATENTANMELDUNG
PI EP 623852 A1 19941109
OD 19941109
AI EP 1994-107156 19940506
PRAI JP 1993-106406 19930507

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

AN 623852 EUROPATFULL ED 19981101 EW 199843 FS PS
TIEN Resist compositions for circuit boards.
TIDE Resistzusammensetzungen fuer gedruckte Schaltungen.
TIFR Compositions formant reserve pour circuits imprimes.
IN Kawade, Masato, c/o Ibiden Co., Ltd., 1-1, Kitaka, Ibigawa-cho, Ibi-gun, Gifu, JP;
Asai, Motoo, c/o Ibiden Co., Ltd., 1-1, Kitaka, Ibigawa-cho, Ibi-gun, Gifu, JP
PA IBIDEN CO, LTD., 1, Kanda-cho 2-chome, Ogaki-shi Gifu 503, JP
PAN 473321
AG Gruenecker, Kinkeldey, Stockmair & Schwanhaeusser Anwaltssozietaet, Maximilianstrasse 58, 80538 Muenchen, DE
AGN 100721
OS EPB1998057 EP 0623852 B1 981021
SO Wila-EPS-1998-H43-T2
DT Patent
LA Anmeldung in Englisch; Veroeffentlichung in Englisch
DS R DE; R GB; R NL
PIT EPB1 EUROPAEISCHE PATENTSCHRIFT
PI EP 623852 B1 19981021
OD 19941109
AI EP 1994-107156 19940506
PRAI JP 1993-106406 19930507
REP DE 3717199 A US 5175060 A
REN PATENT ABSTRACTS OF JAPAN vol. 014, no. 001 (P-985) 8 January 1990 &
JP-A-01253730 (IBIDEN CO LTD) 11 October 1989
ABEN A resist composition having an excellent heat resistance and capable of sufficiently withstanding to an alkali bath at pH of not less than 14 and a bath temperature of 80.degree.C is provided without degrading photosensitive properties by using an uncured novolac type epoxy resin, a part of epoxy group of which is acrylated, as a resin component of a photosensitive resin matrix and adding an imidazole curing agent. <image>

L3 ANSWER 17 OF 35 PROMT COPYRIGHT 2000 Gale Group

AN 1998:149751 PROMT
TI Advanced Viral Research Corp. Announces Extension of Research Agreement with National Cancer Institute
SO PR Newswire, (24 Mar 1998) pp. 0324NYTU003.
LA English
WC 325
FULL TEXT IS AVAILABLE IN THE ALL FORMAT
AB YONKERS, N.Y., March 24 /PRNewswire/ -- Advanced Viral Research Corp. (OTC Bulletin Board: ADVR) today announced that its Materials Transfer Agreement-Cooperative Research and Development Agreement (MTA-CRADA) with
the National Cancer Institute (NCI) for research with ADVR's flagship drug, **Reticulose**, has been extended for one year, beginning March 4, 1998 and ending March 3, 1999.
Reticulose is a non-toxic immunomodulator that has been shown to have a broad spectrum of antiviral therapeutic effects in patients. At the NCI, **Reticulose** is being used to study the basic mechanisms of immune responses. This scientific research is led by Dr. Howard Young, Section Chief in the Laboratory of Experimental Immunology at the NCI, an expert on interferon-gamma. Using kidney tumor model systems, Dr. Young is investigating the anti-tumor activity of **Reticulose**. In addition, Dr. Young and his colleagues will study the effects of **Reticulose** on inflammation associated with **rheumatoid** arthritis.
"The extension of this collaborative agreement between Advanced Viral Research Corp. and one of the premier immunology research laboratories is an important event. We expect these research efforts to provide new insights into the therapeutic potentials, and uses of **Reticulose** while adding to our basic understanding of the workings of the immune system," stated Dr. Shalom Z. Hirschman, President and Chief Executive Officer of Advanced Viral Research Corp.
This news release contains forward-looking statements that involve risks and uncertainties, including risks associated with clinical development, regulatory approvals, including application to the FDA, product commercialization and other risks described from time to time in the SEC reports filed by ADVR. **Reticulose** is not approved by the U.S. Food and Drug Administration or any comparable agencies of any other countries.

SOURCE: Advanced Viral Research Corp.

-0- 03/24/98
/CONTACT: Stephanie Brooks or Valerie Itkin, both of SCIENS WorldWide, for ADVR, 212-771-5500/
(ADVR)
CO: Advanced Viral Research Corporation, National Cancer Institute
ST: New York
IN: MTC
SU:
LR-KE
-- NYTU003 --
2497 03/24/98 07:30 EST http://www.prnewswire.com

L3 ANSWER 18 OF 35 PROMT COPYRIGHT 2000 Gale Group

AN 1999:519129 PROMT
TI SECTION 2: PRESS ACCESSORIES & SUPPLIES.
SO Printing Impressions, (July 1997) Vol. 40, No. 2, pp. 84(1).
ISSN: 0032-860X.
PB North American Publishing Company
DT Newsletter
LA English
WC 21712
FULL TEXT IS AVAILABLE IN THE ALL FORMAT
AB Blankets: Printing Press
THIS IS THE FULL TEXT: COPYRIGHT 1997 North American Publishing Company

L3 ANSWER 19 OF 35 PROMT COPYRIGHT 2000 Gale Group

AN 1999:806188 PROMT
TI Categorical Listing of Suppliers.
SO Shopping Center World, (30 Sep 1997) Vol. 26, No. 10, pp. 4.
ISSN: 0049-0393.
PB Intertec Publishing Corporation, A PRIMEDIA Co.
DT Newsletter
LA English
WC 123083
FULL TEXT IS AVAILABLE IN THE ALL FORMAT
AB Accounting Audits
THIS IS THE FULL TEXT: COPYRIGHT 1997 Intertec Publishing Corporation, A
PRIMEDIA Co.

Subscription: $68.00 per year. Published monthly.

L3 ANSWER 20 OF 35 EUROPATFULL COPYRIGHT 2000 WILA

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

AN 802456 EUROPATFULL ED 19971102 EW 199743 FS OS
TIEN Resist compositions for circuit boards.
TIDE Resistzusammensetzungen fuer Leiterplatten.
TIFR Compositions formant reserve pour plaquettes a circuits.
IN Kawade, Masato, c/o Ibiden Co., Ltd., 1-1, Kitaka, Ibigawa-cho, Ibi-gun, Gifu, JP;
Asai, Motoo, c/o Ibiden Co., Ltd., 1-1, Kitaka, Ibigawa-cho, Ibi-gun, Gifu, JP
PA IBIDEN CO, LTD., 1, Kanda-cho 2-chome, Ogaki-shi Gifu 503, JP
PAN 473321
AG Gruenecker, Kinkeldey, Stockmair & Schwanhaeusser Anwaltssozietaet, Maximilianstrasse 58, 80538 Muenchen, DE
AGN 100721
OS ESP1997064 EP 0802456 A1 971022
SO Wila-EPZ-1997-H43-T2a
DT Patent
LA Anmeldung in Englisch; Veroeffentlichung in Englisch
DS R DE; R GB; R NL
PIT EPA1 EUROPAEISCHE PATENTANMELDUNG
PI EP 802456 A1 19971022
OD 19971022
AI EP 1997-110145 19940506
PRAI JP 1993-106406 19930507
RLI EP 623852 DIV
ABEN A resist composition having an excellent heat resistance and capable of sufficiently withstanding to an alkali bath at pH of not less than 14 and a bath temperature of 80.degree.C is provided without degrading photosensitive properties by using an uncured novolac type epoxy resin, a part of epoxy group of which is acrylated, as a resin component of a photosensitive resin matrix and adding an imidazole curing agent. <image>

L3 ANSWER 21 OF 35 EUROPATFULL COPYRIGHT 2000 WILA

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

AN 771800 EUROPATFULL ED 19970604 EW 199719 FS OS
TIEN Dioxino derivatives and their use as dopamine agonists.
TIDE Dioxinoderivate und ihre Verwendung als Dopamine-Agonisten.
TIFR Derives dioxino et leur utilisation comme agonistes de la dopamine.
IN Stack, Gary Paul, 25 Brookfield Lane, Ambler, Pennsylvania, 19002, US;
Mewshaw, Richard Eric, 21 Boxwood Drive, Princeton, New Jersey, 08540, US;
Bravo, Byron Abel, 29-05 Fox Run Drive, Plainsboro, New Jersey 08536, US;
Kang, Young Hee, 324 Andover Place, Robbinsville, New Jersey, 08691, US
PA AMERICAN HOME PRODUCTS CORPORATION, Five Giralda Farms, Madison, New
Jersey 07940-0874, US
PAN 201462
AG Connelly, Michael John, c/o Patent Department Wyeth Laboratories Huntercombe Lane South Taplow, Maidenhead Berkshire SL6 0PH, GB
AGN 52262
OS ESP1997025 EP 0771800 A2 970507
SO Wila-EPZ-1997-H19-T1a
DT Patent
LA Anmeldung in Englisch; Veroeffentlichung in Englisch
DS R AT; R BE; R CH; R DE; R DK; R ES; R FI; R FR; R GB; R GR; R IE; R IT;
R LI; R LU; R NL; R PT; R SE
PIT EPA2 EUROPAEISCHE PATENTANMELDUNG
PI EP 771800 A2 19970507
OD 19970507
AI EP 1996-307616 19961022
PRAI US 1995-7283 19951106
US 1996-730267 19961015
ABEN The compounds of formula I: <image> wherein R.sup1. and R.sup2. are, independently, hydrogen, alkyl, phenyl or benzyl; or R.sup1. and R.sup2,. taken together, are benzylidene optionally substituted with R.sup3. as defined below or alkylidene, or R.sup1. and R.sup2., taken together with the carbon to which they are attached, form a carbonyl moiety or a cycloalkyl group; R.sup3. is hydrogen, hydroxy, halo, trifluoromethyl, trifluoromethoxy, alkyl, alkoxy, aralkoxy, alkanoyloxy, amino, mono- or di-alkylamino, alkanamido or alkanesulfonamido; R.sup4. is hydrogen or alkyl; m is an integer 0, 1 or 2; n is an integer from 0 to 6, inclusive; Z is hydrogen, hydroxy, alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, polycyclo-alkyl, phenyl optionally substituted with R.sup3. as defined above, phenoxy optionally substituted with R.sup3. as defined above, naphthyl optionally substituted with R.sup3. as defined above or naphthyloxy optionally substituted with R.sup3. as defined above, heteroaryl or heteroaryloxy, in which the heterocyclic ring of the heteroaryl or heteroaryloxy group is selected from thiophene, furan, pyridine, pyrazine, pyrimidine, indole, indazole, imidazole, chroman, coumarin, carbostyril, quinoline, benzisoxazole, benzoxazole, pyrazole, pyrrole, thiazole, oxazole, or isoxazole and the heterocyclic ring is optionally substituted by R.sup3. as defined above; or a pharmaceutically acceptable salt thereof, are useful in treating disorders of the dopaminergic system.

L3 ANSWER 22 OF 35 EUROPATFULL COPYRIGHT 2000 WILA

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

AN 504063 EUROPATFULL ED 19970710 EW 199726 FS PS
TIEN Transceiver for the simultaneous bidirectional baseband transmission of data.
TIDE Sender-Empfaenger fuer gleichzeitige, bidirektionelle Datenuebertragung im Basisband.
TIFR Emetteur-recepteur pour la transmission bidirectionelle simultanee de donnees en bande de base.
IN Marbot, Roland, 121, avenue de Malakoff, F-75116 Paris, FR
PA BULL S.A., 68, route de Versailles, 78430 Louveciennes, FR
PAN 244471
AG Colombe, Michel et al, Direction de la Propriete Intellectuelle BULL SA Poste courrier:LV 59C18 68 route de Versailles, 78430 Louveciennes, FR
AGN 46243
OS EPB1997041 EP 0504063 B1 970625
SO Wila-EPS-1997-H26-T2
DT Patent
LA Anmeldung in Franzoesisch; Veroeffentlichung in Franzoesisch
DS R AT; R BE; R CH; R DE; R ES; R FR; R GB; R IT; R LI; R NL; R SE
PIT EPB1 EUROPAEISCHE PATENTSCHRIFT
PI EP 504063 B1 19970625
OD 19920916
AI EP 1992-400662 19920312
PRAI FR 1991-3127 19910314
REP EP 220626 A US 3700831 A
US 3909559 A

L3 ANSWER 23 OF 35 EUROPATFULL COPYRIGHT 2000 WILA

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

AN 745673 EUROPATFULL ED 19970307 EW 199649 FS OS
TIEN Catalytic antibody regulated prodrug therapy.
TIDE Katalytische Antikoerper-regulierte Prodrugtherapie.
TIFR Therapie promedicamenteuse regulee par des anticorps catalytiques.
IN Blackburn, George Michael, Dep. of Chemistry, University of Sheffield, Sheffield, GB-S37 HF, GB;
Wentworth, Paul, Dep. of Molecular Biology MB34, Scripps Res. Inst., 10666 North Torrey Pines Road, La Jolla, California 92037, US
PA ZENECA LIMITED, 15 Stanhope Gate, London W1Y 6LN, GB
PAN 1579441
AG Giles, Allen Frank et al, Intellectual Property Department ZENECA Pharmaceuticals Alderley Park, Macclesfield, Cheshire SK10 4TG, GB
AGN 80171
OS ESP1996065 EP 0745673 A2 961204
SO Wila-EPZ-1996-H49-T1a
DT Patent
LA Anmeldung in Englisch; Veroeffentlichung in Englisch
DS R CH; R DE; R FR; R GB; R IT; R LI
PIT EPA2 EUROPAEISCHE PATENTANMELDUNG
PI EP 745673 A2 19961204
OD 19961204
AI EP 1996-303643 19960522
PRAI GB 1995-10830 19950527
ABEN Catalytic antibodies capable of catalysing activation of a carbamate (-O-CO-NH-) containing prodrug suitable for Antibody Directed Abzyme Prodrug Therapy (ADAPT) by catalysing breakdown of the prodrug at the carbamate position by a non-spontaneous reaction mechanism. The non-spontaneous reaction preferably has a B.subAc.2 mechanism and the prodrug is a preferably a nitrogen mustard aryl carbamate. The invention also includes relevant immunogens, screens for catalytic activity using short transition state analogues and ADAPT systems.

L3 ANSWER 24 OF 35 EUROPATFULL COPYRIGHT 2000 WILA

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

AN 693489 EUROPATFULL ED 19970108 EW 199604 FS OS
TIEN Heterocyclic tachykinin receptor antagonists.
TIDE Heterocyclische Tachykinin-Rezeptor-Antagonisten.
TIFR Antagonistes heterocycliques du recepteur des tachykinines.
IN Cho, Sung-Yong Stephen, 49 Showers Drive No. B451, Mountain View, California 94040, US;
Copp, James Densmore, 2031 Foxmoor Terrace, Greenwood, Indiana 46143, US;
Ginah, Francis Orerenyo, 2225 Broadway, Indianapolis, Indiana 46205, US;
Hansen, Guy Joe, 5235 Camden, Indianapolis, Indiana 46227, US;
Hipskind, Philip Arthur, 3660 South Farmstone Circle, New Palestine, Indiana 46163, US;
Huff, Bret Eugene, 201 Oak Hill Lane, Mooresville, Indiana 46158, US;
Martinelli, Michael John, 5242 Wilton Wood Court, Indianapolis, Indiana 46254, US;
Staszak, Michael Alexander, 4515 North Lakeridge Drive, Indianapolis, Indiana 46234, US;
Tharp-Taylor, Roger William, 14965 Allisonville Road, Noblesville, Indiana 46060, US
PA ELI LILLY AND COMPANY, Lilly Corporate Center, Indianapolis, Indiana 46285, US
PAN 204942
AG Tapping, Kenneth George et al, Lilly Industries Limited European Patent Operations Erl Wood Manor, Windlesham Surrey GU20 6PH, GB
AGN 52302
OS ESP1996005 EP 0693489 A1 960124
SO Wila-EPZ-1996-H04-T1a
DT Patent
LA Anmeldung in Englisch; Veroeffentlichung in Englisch
DS R AT; R BE; R CH; R DE; R DK; R ES; R FR; R GB; R GR; R IE; R IT; R LI;
R LU; R NL; R PT; R SE
PIT EPA1 EUROPAEISCHE PATENTANMELDUNG
PI EP 693489 A1 19960124
OD 19960124
AI EP 1995-304750 19950707
PRAI US 1994-271708 19940712
ABEN This invention provides the novel compound of the following formula <image> having the chemical name (R)-3-(1H-indol-3-yl)-1-[N-(2-methoxybenzyl)acetylamino]-2-[N-(2-(4-(piperidin-1-yl)piperidin-1-yl)acetyl)amino]propane dihydrochloride trihydrate.

L3 ANSWER 25 OF 35 EUROPATFULL COPYRIGHT 2000 WILA

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

AN 509769 EUROPATFULL ED 19970307 EW 199637 FS PS
TIEN Heterocyclic amides having HLE inhibiting activity.
TIDE HLE-inhibierende heterozyklische Amide.
TIFR Amides heterocycliques ayant une activite inhibante de HLE.
IN Bernstein, Peter Robert, ICI Americas Inc, Concord Pike & New Murphy Road, Wilmington DE, US;
Shaw, Andrew, ICI Americas Inc, Concord Pike & New Murphy Road, Wilmington DE, US;
Thomas, Royston Martin, ICI Americas Inc, Concord Pike & New Murphy Road, Wilmington DE, US;
Wolanin, Donald John, ICI Americas Inc, Concord Pike & New Murphy Road, Wilmington DE, US;
Warner, Peter, Alderley Park, Macclesfield, Cheshire SK10 4TG, GB
PA ZENECA LIMITED, 15 Stanhope Gate, London W1Y 6LN, GB
PAN 1579441
AG Smith, Stephen Collyer et al, Intellectual Property Department ZENECA Pharmaceuticals Mereside Alderley Park, Macclesfield Cheshire SK10 4TG, GB
AGN 43083
OS EPB1996057 EP 0509769 B1 960911
SO Wila-EPS-1996-H37-T1
DT Patent
LA Anmeldung in Englisch; Veroeffentlichung in Englisch
DS R DE; R FR; R GB; R IT
PIT EPB1 EUROPAEISCHE PATENTSCHRIFT
PI EP 509769 B1 19960911
OD 19921021
AI EP 1992-303358 19920415
PRAI GB 1991-8358 19910418
GB 1991-8357 19910418
GB 1992-5392 19920312
REP EP 189305 A US 4474778 A
REN BIOCHEMISTRY. vol. 25, no. 13, 1 July 1986, EASTON, PA US pages 3760 -
3767 B IMPERIALI AND R H ABELES 'inhibition of serine proteases by peptidyl fluoromethyl ketones'

L3 ANSWER 26 OF 35 FROSTI COPYRIGHT 2000 LFRA
AN 382293 FROSTI
TI Information - an essential raw material for the food industry.
AU Leadbetter S.
SO European Food and Drink Review, 1995, (Spring), 73-75 (0 ref.)
DT Journal
LA English
SL English
AB New developments in information technology are discussed. On-line access to databases either directly through the database producer or through a public access host is described. The use of CD-ROM for the bulk of everyday research with on-line access for the most current and up-to-date material is recommended. It is emphasised that the food industry needs to be in touch with key technical, legal and commercial advances quickly and simply. The ways in which developments in information technology can simplify the complexities of international food legislation, harness information for successful **product** R&D and realise the strategic benefits of food market intelligence are discussed. The series of databases produced by the Leatherhead Food RA is listed.

L3 ANSWER 27 OF 35 IFIPAT COPYRIGHT 2000 IFI
AN 2459021 IFIPAT;IFIUDB;IFICDB
TI SELF-COHERENCE RESTORING SIGNAL EXTRACTION AND ESTIMATION OF SIGNAL
DIRECTION OF ARRIVAL
INF Agee, Brian G, San Jose, CA
Gardner, William A, Yountville, CA
Schell, Stephan V, Livermore, CA
IN Agee Brian G; Gardner William A; Schell Stephan V

PAF The Regents of the University of California, Oakland, CA
PA California, University of Regents (13234)
EXNAM Black, Thomas G
EXNAM Zanelli, Michael
AG O'Banion, John P
PI US 5299148 19940329 (CITED IN 006 LATER PATENTS)
AI US 1990-526840 19900522
XPD 29 Mar 2011
RLI US 1988-264256 19881028 CONTINUATION-IN-PART ABANDONED
FI US 5299148 19940329
DT UTILITY
FS ELECTRICAL
GOVI This invention was made with Government support under Grant/Contract No. MIP-88-12902 awarded by the National Science Foundation. Additional support was provided by the Army Research Office under contract No. DAAL03-89-C-0035 through Statistical Signal Processing, Inc. The Government has certain rights in this invention.
MRN 005561 MFN: 0728
CLMN 41
GI 16 Drawing Sheet(s), 19 Figure(s).
AB A processor and method for extracting or estimating directions of arrival of signals from a received data vector x(t) which has been corrupted by interfering signals and noise is described. The processor extracts signals by forming the scalar product of x(t) and a weight vector which is chosen such that the spectral selfcoherence or conjugate spectral self-coherence of the processor output is maximized. The processor estimates the directions of arrival of signals by spectral self-coherence-selective performance surfaces for maxima.

L3 ANSWER 28 OF 35 MEDLINE
AN 88116869 MEDLINE
DN 88116869
TI Quantitative evaluation of regional myocardial blood flow by digital subtraction angiography: correlations with exercise electrocardiography and Tl-201 myocardial scintigraphy.
AU Ikeda H; Shibao K; Yamaguchi R; Yoh M; Shimamatsu M; Hiyamuta K; Itaya K;
Ohkita Y; Sugi K; Koga Y; et al
CS Third Department of Internal Medicine, Kurume University, School of Medicine..
SO JOURNAL OF CARDIOGRAPHY. SUPPLEMENT, (1987) 12 81-9.
Journal code: AKN. ISSN: 0386-2887.
CY Japan
DT Journal; Article; (JOURNAL ARTICLE)
LA Japanese
FS Priority Journals
EM 198805
AB We previously reported that the contrast disappearance half-life (T1/2) derived by the computerized washout analysis of digital subtraction coronary arteriograms provides a useful index for quantitatively evaluating regional myocardial blood flow. In the present study, we further evaluated the clinical usefulness of T1/2, comparing it with exercise electrocardiography and exercise thallium-201 myocardial scintigraphy. The study subjects consisted of 25 patients with angina pectoris and 14 patients with normal coronary arteries. Following the manual injection of contrast media into the left anterior descending coronary artery (LAD), a time-density curve was generated in the sectors of the myocardium which were perfused by the LAD and the T1/2 was calculated. T1/2 values correlated closely with double **product** (r = -0.73). They were significantly greater in patients with exercise-induced ST depression (8.3 +/- 1.0 vs 5.8 +/- 0.7, p less than 0.005). In addition, there was a good correlation between T1/2 values and washout ratio as determined by exercise thallium-201 myocardial scintigraphy, with r = -0.83. Although T1/2 values were within the normal range (mean +/- 2SD of control subjects) in all patients with LAD stenosis of 50 percent or less, these values were abnormally increased, exceeding the normal range, in 11 of the 12 patients with stenosis of 90 percent or more. Compared with exercise electrocardiography, T1/2 values were abnormally prolonged in 11 of the 13 patients with exercise-induced ST depression. Compared with exercise thallium-201 myocardial scintigraphy, T1/2 values were abnormally prolonged in seven of the nine patients with transient perfusion defects.(ABSTRACT TRUNCATED AT 250 WORDS)

L3 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2000 ACS
AN 1985:489646 CAPLUS
DN 103:89646
TI Exact uniqueness and multiplicity criteria for, and steady state and dynamic behavior of an isothermal CSTR with general autocatalytic reactions. No **product R** in feed
AU Chi, Jung Chang
CS Dep. Chem. Eng., Tamkang Univ., Tamsui, 251, Taiwan
SO J. Chin. Inst. Chem. Eng. (1985), 16(2), 133-44
CODEN: JCICAP; ISSN: 0368-1653
DT Journal
LA English
AB An isothermal, continuous-flow, stirred-tank reactor (CSTR) is analyzed in the case of an autocatalytic reaction of the general type A .fwdarw. .alpha.R + P, -rA = k1CAnCRm/(1 + k2CA)p without feeding R. Exact crit. for uniqueness and multiplicity of steady states as well as stable steady states are established. Steady-state behavior with changing Damkohler no. and dynamic reactor behavior on the phase plane are discussed. The max. no. of steady-state solns. is 4 with m <1 and 3 with m .gtoreq.1. The system can have at most 2 stable steady states. All stable steady states are nodes, all unstable steady states are saddle points, and no limit cycles exist. Graphs showing regions of uniqueness and multiplicity of stable steady states in parameter space are given.

L3 ANSWER 30 OF 35 COPYRIGHT 2000 PJB

AN 83:9093 PHIN
DN C00009784
DED 24 Jun 1983
TI CooperBiomedical's share offer
SO Clinica (1983) No. 70 p8
DT Newsletter
FS FULL

L3 ANSWER 31 OF 35 IFIPAT COPYRIGHT 2000 IFI
AN 0880300 IFIPAT;IFIUDB;IFICDB
TI CAPACITANCE MULTIPLIER AND FILTER SYNTHESIZING NETWORK
INF Fletcher, James C Administrator of the National Aeronautics and Space Administration with respect to an invention by, , Scottsdale, AZ, 85251
Kline, Arthur J, 6453 E Monta Rosa St, Scottsdale, AZ, 85251
IN FLETCHER J; KLINE A
PAF Unassigned
PA U S OF AMERICA NASA ADMINISTRATOR OF (86504)
EXNAM Kaufman, Nathan
AG Manning, John R
McCaul, Paul F
Mott, Monte F
PI US 3831117 19740820 (CITED IN 016 LATER PATENTS)
AI US 1972-306652 19721115
XPD 20 Aug 1991
FI US 3831117 19740820
DT UTILITY
FS ELECTRICAL
CLMN 5
GI 1 Drawing Sheet(s), 4 Figure(s).
AB A circuit using a differential amplifier multiplies the capacitance of a discrete integrating capacitor by (R1 + R2)/R2 where R1 and R2 are values of discrete resistor coupling an input signal e1 to the amplifier inputs. The output eo of the amplifier is fed back and added to the signal coupled by the resistor R2 to the amplifier through a resistor of value R1. A discrete resistor Rx may be connected in series for a lag filter and a discrete resistor may be connected in series with the capacitor for a lead-lag filter. Voltage dividing resistors **Ra** and Rb may be included in the feedback circuit of the amplifier output eo to independently adjust the overall circuit gain ei/eo.

L3 ANSWER 32 OF 35 MEDLINE
AN 73070738 MEDLINE
DN 73070738
TI [Diffuse lymphoreticulosis of the orbit].
La lympho-**reticulose** diffuse de l'orbite.
AU Cernea P; Dobrescu G
SO ANNALES D OCULISTIQUE, (1972 Jul) 205 (7) 775-86.
Journal code: 5OU. ISSN: 0003-4371.
CY France
DT Journal; Article; (JOURNAL ARTICLE)
LA French
FS Priority Journals
EM 197304

L3 ANSWER 33 OF 35 MEDLINE

AN 69267885 MEDLINE
DN 69267885
TI [Generalized follicular mucinosis revealing cutaneous and bronchopulmonary histiomonocytic reticulosis oa case].
Mucinose folliculaire generalisee revelatrice d'une **reticulose** histiomonocytaire `a localisations cutanees et broncho-pulmonaires.
Epilogue d'une observation.
AU Grosshans E; Bohner C; Weitzenblum E; Rousselot P; Maleville J; Basset A
SO SEMAINE DES HOPITAUX, (1969 May 14) 45 (23) 1626-33.
Journal code: ULD. ISSN: 0037-1777.
CY France
DT Journal; Article; (JOURNAL ARTICLE)
LA French
FS Priority Journals
EM 196911

L3 ANSWER 34 OF 35 MEDLINE
AN 70201004 MEDLINE
DN 70201004
TI [Giant-cell multicentric histiocytic reticulosis].
Reticulose histiocytaire multi-centrique giganto-cellulaire.
AU Stewart W M; Metayer; Lecrocq C; Lauret P; Chegaray E
SO BULLETIN DE LA SOCIETE FRANCAISE DE DERMATOLOGIE ET DE SYPHILIGRAPHIE,
(1969) 76 (6) 814-7.
Journal code: C0G. ISSN: 0049-1071.
CY France
DT Journal; Article; (JOURNAL ARTICLE)
LA French
FS Priority Journals
EM 197009

L3 ANSWER 35 OF 35 MEDLINE
AN 69178108 MEDLINE
DN 69178108
TI [Histiocytic reticulosis in infants or Letterer-Siwe disease. (Clinical and therapeutical study)].
La **reticulose** histiocytaire du nourrisson ou maladie de Letterer-Siwe. (Etude clinique et therapeutique).
AU Marie J; Hennequet A; Leveque B; Debauchez C; Desbois C; Watchi J M
SO ANNALES DE PEDIATRIE, (1968 Nov 2) 15 (11) 681-96.
Journal code: 5UC. ISSN: 0066-2097.
CY France
DT Journal; Article; (JOURNAL ARTICLE)
LA French
EM 196908

=> file uspatfull
=> s l1
L4 128 (RETICULOSE OR PRODUCT (W) "R") AND (RHEUMATOID OR RA)
=> s l4 and arthritis
13839 ARTHRITIS
L5 80 L4 AND ARTHRITIS

=> d 1-80 bib ab

L5 ANSWER 1 OF 80 USPATFULL
AN 2000:31435 USPATFULL
TI Fluorinated butyric acids and their derivatives as inhibitors of matrix metalloproteinases
IN Roth, Bruce David, Plymouth, MI, United States
O'Brien, Patrick Michael, Stockbridge, MI, United States
Sliskovic, Drago Robert, Saline, MI, United States
PA Warner-Lambert Company, Ann Arbor, MI, United States (U.S. corporation)
PI US 6037361 20000314
AI US 1998-36751 19980309 (9)
DT Utility
EXNAM Primary Examiner: Kight, John; Assistant Examiner: Covington, Raymond
LREP Merchant & Gould P.C.
CLMN Number of Claims: 32
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1247
AB Fluorinated butyric acid compounds and derivatives are described as well as acid methods for the preparation and pharmaceutical compositions of same, which are useful as inhibitors of matrix metalloproteinases, particularly gelatinase A (72 kD gelatinase) and stromelysin-1, and also collagenase, matrilysin, and MMP-13, and for the treatment of multiple sclerosis, atherosclerotic plaque rupture, aortic aneurism, heart failure, restenosis, periodontal disease, corneal ulceration, treatment of burns, decubital ulcers, wound healing, cancer, inflammation, pain, **arthritis**, or other autoimmune or inflammatory disorders dependent upon tissue invasion by leukocytes or other activated migrating cells, acute and chronic neurodegenerative disorders including stroke, head trauma, spinal cord injury, Alzheimer's disease, amyotrophic lateral sclerosis, cerebral amyloid angiopathy, AIDS, Parkinson's disease, Huntington's disease, prion diseases, myasthenia gravis, and Duchenne's muscular dystrophy.

L5 ANSWER 2 OF 80 USPATFULL
AN 2000:9904 USPATFULL
TI Heterocyclic compounds
IN Hohlweg, Rolf, Kvistgaard, Denmark
PA Novo Nordisk A/S, Bagsvaerd, Denmark (non-U.S. corporation)
PI US 6017915 20000125
AI US 1998-79599 19980515 (9)
RLI Division of Ser. No. US 1996-715665, filed on 18 Sep 1996, now patented, Pat. No. US 5753678
PRAI DK 1995-1040 19950919
DK 1995-1041 19950919
DT Utility
EXNAM Primary Examiner: Kight, John; Assistant Examiner: Aislakh, Charanjit S.
LREP Zelson, Steve T.; Rozek, Carol E.
CLMN Number of Claims: 5
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 890
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to novel N-substituted amino alcohols, amino acids and acid derivatives thereof in which a substituted alkyl chain forms part of the N-substituent or salts thereof, to methods for their preparation, to compositions containing them, and to their use for the clinical treatment of painful, hyperalgesic and/or inflammatory conditions in which C-fibers play a pathophysiological role by eliciting neurogenic pain or inflammation.

L5 ANSWER 3 OF 80 USPATFULL
AN 1999:137513 USPATFULL
TI 1-substituted, 2-substituted 1H-imidazo[4,5-c] quinolin-4-amines
IN Gerster, John F., Woodbury, MN, United States
Crooks, Stephen L., Mahtomedi, MN, United States
Lindstrom, Kyle J., Houlton, WI, United States
PA 3M Innovative Properties Company, St. Paul, MN, United States (U.S. corporation)
PI US 5977366 19991102
AI US 1998-60010 19980414 (9)
RLI Division of Ser. No. US 1997-789264, filed on 28 Jan 1997, now patented, Pat. No. US 5741909 which is a division of Ser. No. US 1994-353802, filed on 12 Dec 1994, now patented, Pat. No. US 5605899 which is a division of Ser. No. US 1992-938295, filed on 28 Aug 1992, now patented, Pat. No. US 5389640 which is a continuation-in-part of Ser. No. US 1992-838475, filed on 19 Feb 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-687326, filed on 18 Apr 1991, now abandoned which is a continuation-in-part of Ser. No. US 1991-662926, filed on 1 Mar 1991, now abandoned
DT Utility
EXNAM Primary Examiner: Rotman, Alan L.
LREP Howard, MarySusan; Ringsred, Ted K.; Sprague, Robert W.
CLMN Number of Claims: 2
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2303
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB 1-substituted, 2-substituted 1H-imidazo[4,5-c]-quinolin-4-amines are disclosed. These compounds function as antiviral agents, they induce biosynthesis of interferon, and they inhibit tumor formation in animal models. This invention also provides intermediates for preparing such compounds, pharmaceutical compositions containing such compounds, and pharmacological methods of using such compounds.

L5 ANSWER 4 OF 80 USPATFULL
AN 1999:132809 USPATFULL
TI Heterocyclic compounds

IN Hohlweg, Rolf, Kvistgaard, Denmark
PA Novo Nordisk A/S, Bagsvaerd, Denmark (non-U.S. corporation)
PI US 5972925 19991026
AI US 1997-922977 19970904 (8)
RLI Division of Ser. No. US 1996-715665, filed on 18 Sep 1996
PRAI DK 1995-1040 19950919
DK 1995-1041 19950919
DT Utility
EXNAM Primary Examiner: Rotman, Alan L.; Assistant Examiner: Aulakh, Charanjit S.
LREP Zelson, Steve T.; Lambiris, Elias; Rozek, Carol E.
CLMN Number of Claims: 14
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 918
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to novel N-substituted amino alcohols, amino acids and acid derivatives thereof in which a substituted alkyl chain forms part of the N-substituent or salts thereof, to methods for their preparation, to compositions containing them, and to their use for the clinical treatment of painful, hyperalgesic and/or inflammatory conditions in which C-fibers play a pathophysiological role by eliciting neurogenic pain or inflammation.

L5 ANSWER 5 OF 80 USPATFULL
AN 1999:128543 USPATFULL
TI Tricyclic compounds for the inhibition of the ICE/ced-3 protease family of enzymes
IN Karanewsky, Donald S., Escondido, CA, United States
Linton, Steven D., San Diego, CA, United States
PA Idun Pharmaceuticals, Inc., La Jolla, CA, United States (U.S. corporation)
PI US 5968927 19991019
AI US 1997-928990 19970912 (8)
RLI Continuation-in-part of Ser. No. US 1996-710621, filed on 20 Sep 1996, now abandoned
DT Utility
EXNAM Primary Examiner: Raymond, Richard L.; Assistant Examiner: Kifle, Bruck
LREP Seed and Berry LLP
CLMN Number of Claims: 48
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2053
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention is directed to novel tricyclic ICE/ced-3 family inhibitor compounds. The invention is also directed to pharmaceutical compositions of such tricyclic compounds, plus the use of such compositions in the treatment of patients suffering inflammatory, autoimmune and neurodegenerative diseases, and for the prevention of ischemic injury.

L5 ANSWER 6 OF 80 USPATFULL
AN 1999:110488 USPATFULL
TI Therapeutic compound-fatty acid conjugates
IN Whittaker, Robert George, West Pymble, Australia
Bender, Veronika Judith, Cremorne, Australia
Reilly, Wayne Gerrard, Northmead, Australia
Moghaddam, Minoo, Killara, Australia
PA Commonwealth Scientific and Industrial Research Organisation, Campbell, Australia (non-U.S. corporation)
PI US 5952499 19990914
WO 9622303 19960725
AI US 1997-875098 19970925 (8)
WO 1996-AU15 19960115
19970925 PCT 371 date
19970925 PCT 102(e) date
DT Utility
EXNAM Primary Examiner: Dees, Jose' G.; Assistant Examiner: Badio, Barbara
LREP McDermott, Will & Emery
CLMN Number of Claims: 16
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2128
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A methotrexate conjugated to 1-3 acyl groups derived from fatty acids. In particular the invention relates to altering the pharmacokinetic profile and mode of delivery of methotrexate by conjugating it to 1.2 or 3 acyl derivatives of fatty acids.

L5 ANSWER 7 OF 80 USPATFULL
AN 1999:85629 USPATFULL
TI Inhibitors of metalloproteases, pharmaceutical compositions comprising same and methods of their use
IN Campbell, David A., San Mateo, CA, United States
Patel, Dinesh V., Fremont, CA, United States
Xiao, Xiao-Yi, La Jolla, CA, United States
PA Affymax Technologies N.V., Greenford, United Kingdom (non-U.S. corporation)
PI US 5929278 19990727
AI US 1998-81466 19980519 (9)
RLI Continuation of Ser. No. US 1995-549345, filed on 27 Oct 1995, now patented, Pat. No. US 5831004 which is a continuation-in-part of Ser. No. US 1995-484255, filed on 7 Jun 1995, now abandoned which is a continuation-in-part of Ser. No. US 1994-329420, filed on 27 Oct 1994, now abandoned
DT Utility
EXNAM Primary Examiner: Tsang, Cecilia J.; Assistant Examiner: Delacroix-Muirheid, C.
LREP Swiss, Gerald F.; Stevens, Lauren L.
CLMN Number of Claims: 8
ECL Exemplary Claim: 1
DRWN 17 Drawing Figure(s); 13 Drawing Page(s)
LN.CNT 2235
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed are novel inhibitors of metalloproteases, in particular matrix metalloproteases. The disclosed inhibitors are mercaptoketone and mercaptoalcohol compounds which are useful in pharmaceutical compositions and methods for treating or controlling disease states or conditions which involve tissue breakdown, for example, arthropathy, dermatological conditions, bone resorption, inflammatory diseases, and tumor invasion and in the promotion of wound healing.

L5 ANSWER 8 OF 80 USPATFULL
AN 1999:78711 USPATFULL
TI Morpholine and thiomorpholine tachykinin receptor antagonists
IN Dorn, Conrad P., Plainfield, NJ, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 5922706 19990713
AI US 1997-969685 19971113 (8)
RLI Division of Ser. No. US 1995-525259, filed on 5 Sep 1995, now patented, Pat. No. US 5719147 which is a continuation-in-part of Ser. No. WO 1994-US14497, filed on 13 Dec 1994 And Ser. No. US 1993-169889, filed on 17 Dec 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-61914, filed on 19 May 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-971448, filed on 4 Nov 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-905976, filed on 29 Jun 1992, now abandoned
DT Utility
EXNAM Primary Examiner: Grumbling, Matthew V.
LREP Thies, J. Eric; Rose, David L.
CLMN Number of Claims: 21
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 7932
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Substituted heterocycles of the general structural formula: ##STR1## are tachykinin receptor antagonists useful in the treatment of inflammatory diseases, pain or migraine, asthma and emesis, and calcium channel blockers useful in the treatment of cardiovascular conditions such as angina, hypertension or ischemia.

L5 ANSWER 9 OF 80 USPATFULL
AN 1999:75625 USPATFULL
TI Fucose derivatives, drugs containing the same as active ingredient, and intermediates for producing the same
IN Tsukida, Takahiro, Osaka, Japan
PA Kanebo, Ltd, Tokyo, Japan (non-U.S. corporation)
PI US 5919769 19990706
WO 9715585 19970501
AI US 1998-51846 19980422 (9)
WO 1996-JP3081 19961023
19980422 PCT 371 date
19980422 PCT 102(e) date
PRAI JP 1995-303476 19951026
JP 1996-175487 19960613

JP 1996-231482 19960812
DT Utility
EXNAM Primary Examiner: Lambkin, Deborah C.
LREP Merchant, Gould, Smith, Edell, Welter & Schmidt
CLMN Number of Claims: 7
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3664
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A compound of the formula (I): ##STR1## wherein X.sup.1 is a group of one of the following formulae (1), (2) and (3): ##STR2## R.sup.1 is a branched long chain alkyl group, R.sup.2 is --CONHR.sup.3, a carboxyl group or a hydrogen atom, n is an integer of 0, 1 or 2, and R.sup.3 is a lower alkyl group or a phenyl group, or a pharmaceutically acceptable salt thereof, which is useful as a selectin inhibitor, and can be used in the prophylaxis or treatment of various inflammatory diseases such as inflammatory dermatitis (e.g., atopic dermatitis, contact hypersensitivity, photodermatosis, etc.), autoimmune chronic diseases (e.g. **rheumatoid arthritis**, chronic thyroiditis, etc.), and ischemia-reperfusion injury.

L5 ANSWER 10 OF 80 USPATFULL
AN 1999:72739 USPATFULL
TI Heterocyclic compounds
IN Hohlweg, Rolf, Kvistgaard, Denmark
PA Novo Nordisk A/S, Bagsvaerd, Denmark (non-U.S. corporation)
PI US 5917047 19990629
AI US 1997-957172 19971024 (8)
RLI Division of Ser. No. US 1996-715665, filed on 18 Sep 1996
PRAI DK 1995-1040 19950905
DK 1995-1041 19950905
DT Utility
EXNAM Primary Examiner: Rotman, Alan L.; Assistant Examiner: Aulakh, Charanjit
S.
LREP Zelson, Steve T.; Rozek, Carol E.; Lambiris, Elias J.
CLMN Number of Claims: 6
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 905
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to novel N-substituted amino alcohols, amino acids and acid derivatives thereof in which a substituted alkyl chain forms part of the N-substituent or salts thereof, to methods for their preparation, to compositions containing them, and to their use for the clinical treatment of painful, hyperalgesic and/or inflammatory conditions in which C-fibers play a pathophysiological role by eliciting neurogenic pain or inflammation.

L5 ANSWER 11 OF 80 USPATFULL
AN 1999:72593 USPATFULL
TI Heterocyclic compounds
IN Hohlweg, Rolf, Kvistgaard, Denmark
PA Novo Nordisk A/S, Bagsvaerd, Denmark (non-U.S. corporation)
PI US 5916901 19990629
AI US 1998-79935 19980515 (9)
RLI Division of Ser. No. US 1996-715665, filed on 18 Sep 1996, now patented, Pat. No. US 5753678
PRAI DK 1995-1040 19950919
DK 1995-1041 19950919
DT Utility
EXNAM Primary Examiner: Rotman, Alan L.; Assistant Examiner: Aulakh, Charanjit
S.
LREP Zelson, Steve T.; Lambris, Elias J.; Rozek, Carol E.
CLMN Number of Claims: 9
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 891
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to novel N-substituted amino alcohols, amino acids and acid derivatives thereof in which a substituted alkyl chain forms part of the N-substituent or salts thereof, to methods for their preparation, to compositions containing them, and to their use for the clinical treatment of painful, hyperalgesic and/or inflammatory conditions in which C-fibers play a pathophysiological role by eliciting neurogenic pain or inflammation.

L5 ANSWER 12 OF 80 USPATFULL
AN 1999:67281 USPATFULL
TI Heterocyclic compounds
IN Hohlweg, Rolf, Kvistgaard, Denmark
PA Novo Nordish A/S, Bagsvaerd, Denmark (non-U.S. corporation)
PI US 5912262 19990615
AI US 1997-957163 19971024 (8)
RLI Division of Ser. No. US 1996-715665, filed on 18 Sep 1996
PRAI DK 1995-1040 19950919
DK 1995-1041 19950919
DT Utility
EXNAM Primary Examiner: Rotman, Alan L.; Assistant Examiner: Aulakh, Charanjit
S.
LREP Zelson, Steve T.; Rozek, Carol E.; Lambiris, Elias J.
CLMN Number of Claims: 11
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 907
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to novel N-substituted amino alcohols, amino acids and acid derivatives thereof in which a substituted alkyl chain forms part of the N-substituent or salts thereof, to methods for their preparation, to compositions containing them, and to their use for the clinical treatment of painful, hyperalgesic and/or inflammatory conditions in which C-fibers play a pathophysiological role by eliciting neurogenic pain or inflammation.

L5 ANSWER 13 OF 80 USPATFULL
AN 1999:61253 USPATFULL
TI Peptide derivatives
IN Stein, Mark Morris, Wilmington, DE, United States
Trainor, Diane Amy, Glen Mills, PA, United States
PA Zeneca Inc., Wilmington, DE, United States (U.S. corporation)
PI US 5907068 19990525
AI US 1992-941001 19920904 (7)
RLI Division of Ser. No. US 1990-491757, filed on 9 Mar 1990, now patented, Pat. No. US 5194588 which is a division of Ser. No. US 1987-5538, filed on 20 Jan 1987, now patented, Pat. No. US 4910190 which is a continuation-in-part of Ser. No. US 1986-821150, filed on 21 Jan 1986, now abandoned
PRAI GB 1985-1522 19850122
GB 1985-1523 19850122
GB 1985-1524 19850122
DT Utility
EXNAM Primary Examiner: Tsang, Cecilia J.; Assistant Examiner: Marshall, S. G.
CLMN Number of Claims: 2
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 5465
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention concerns pharmaceutically useful trifluoromethyl ketone substituted di-, tri- and tetra-peptide derivatives of the formulae Ia, Ib, Ic set out hereinafter, and salts thereof which are inhibitors of human leukocyte elastase. Also described herein are pharmaceutical compositions containing a peptide derivative and processes and intermediates for use in the manufacture of the peptide derivatives.

L5 ANSWER 14 OF 80 USPATFULL
AN 1999:22097 USPATFULL
TI Morpholine and thiomorpholine tachykinin receptor antagonists
IN Dorn, Conrad P., Plainfield, NJ, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 5872116 19990216
AI US 1997-959393 19971028 (8)
RLI Division of Ser. No. US 1995-525259, filed on 8 Sep 1995, now patented, Pat. No. US 5719147 And a continuation-in-part of Ser. No. US 1993-169889, filed on 17 Dec 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-61914, filed on 19 May 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-971448, filed on 4 Nov 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-905976, filed on 29 Jun 1992, now abandoned
DT Utility
EXNAM Primary Examiner: Weddington, Kevin E.
LREP Thies, J. Eric; Rose, David L.
CLMN Number of Claims: 21
ECL Exemplary Claim: 1

DRWN No Drawings
LN.CNT 8249
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Substituted heterocycles of the general structural formula: ##STR1## are tachykinin receptor antagonists useful in the treatment of inflammatory diseases, pain or migraine, asthma and emesis, and calcium channel blockers useful in the treatment of cardiovascular conditions such as angina, hypertension or ischemia.

L5 ANSWER 15 OF 80 USPATFULL
AN 1999:12924 USPATFULL
TI Substituted 4-arylbutyric acid derivatives as matrix metalloprotease
IN Kluender, Harold C. E., Trumbull, CT, United States
Dixon, Brian R., Woodbridge, CT, United States
Brittelli, David R., Branford, CT, United States
PA Bayer Corporation, Pittsburgh, PA, United States (U.S. corporation)
PI US 5863915 19990126
AI US 1997-857004 19970515 (8)
PRAI US 1996-51008 19960515 (60)
DT Utility
EXNAM Primary Examiner: Shah, Mukund J.; Assistant Examiner: Rao, Deepak R.
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1430
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Inhibitors for matrix metalloproteases, pharmaceutical compositions containing them, and a process for using them to treat a variety of physiological conditions. The compounds of the invention have the generalized formula ##STR1## wherein R.sup.1 represents C.sub.6 -C.sub.12 alkyl; C.sub.5 -C.sub.12 alkoxy; C.sub.5 -C.sub.12 alkylthio; a polyether of formula R.sup.2 O(C.sub.2 H.sub.4 O).sub.a -- in which a is 1 or 2 and R.sup.2 is C.sub.1 -C.sub.5 alkyl, phenyl, or benzyl; and substituted alkynyl of formula R.sup.3 (CH.sub.2).sub.b --C.tbd.C--; in which b is 1-10 and R.sup.3 is H--, HO--, or R.sup.4 O-- in which R.sup.4 is C.sub.1 -C.sub.3 alkyl, phenyl, or benzyl. The alkyl, phenyl, and benzyl portions of R.sup.1 may bear at least one pharmaceutically-acceptable substituent. The subscript n is 2-4. R.sup.5 represents phenyl; imidoyl of 4-12 carbon atoms; (3H)-benzo-1,2,3-triazin-4-on-3-yl; N-saccharinyl; (2H)-phthalazin-1-on-2-yl; 2-benzoxazolin-2-on-3-yl; 5,5-dimethyloxazolidine-2,4-dion-3-yl; and thiazolidine-2,4-dion-3-yl; with the phenyl and benzo portions of R.sup.5 permissibly bearing at least one pharmaceutically-acceptable substituent. Pharmaceutically acceptable salts of these materials are also included.

L5 ANSWER 16 OF 80 USPATFULL
AN 1998:162483 USPATFULL
TI Sialyl Le.sup.x analogues as inhibitors of cellular adhesion
IN DeFrees, Shawn A., San Marcos, CA, United States
PA Cytel Corporation, San Diego, CA, United States (U.S. corporation)
PI US 5854218 19981229
AI US 1996-730553 19961015 (8)
RLI Continuation-in-part of Ser. No. US 1995-485453, filed on 7 Jun 1995 which is a continuation-in-part of Ser. No. US 1994-345072, filed on 28 Nov 1994, now patented, Pat. No. US 5604207 which is a continuation-in-part of Ser. No. US 1994-241645, filed on 12 May 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-62120, filed on 14 May 1993, now abandoned
PRAI US 1995-5545 19951018 (60)
DT Utility
EXNAM Primary Examiner: Fonda, Kathleen K.
LREP Townsend and Townsend and Crew LLP
CLMN Number of Claims: 5
ECL Exemplary Claim: 1
DRWN 23 Drawing Figure(s); 23 Drawing Page(s)
LN.CNT 4217
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to analogues of sialyl Le.sup.x that inhibit cellular adhesion between a selectin and cells that express sialyl Le.sup.x on their surfaces, as well as methods and compositions using the same, intermediates and methods for the preparation of the cellular adhesion inhibitor compounds and their intermediates. A contemplated intermediate or inhibitor compound has a structure that corresponds to that of Formula A, ##STR1##

L5 ANSWER 17 OF 80 USPATFULL
AN 1998:156821 USPATFULL
TI Composition containing peptides and nucleic acids and methods of making same
IN Kochel, Bonawentura, Wroclaw, Poland
PA Immune Modulation Maximum, New York, NY, United States (U.S. corporation)
PI US 5849196 19981215
AI US 1996-726650 19961007 (8)
DT Utility
EXNAM Primary Examiner: Elliott, George C.; Assistant Examiner: Larson, Thomas G.LREP Carrier, Blackman & Associates, P.C.; Carrier, Joseph P.; Esser, William F.
CLMN Number of Claims: 16
ECL Exemplary Claim: 9
DRWN 6 Drawing Figure(s); 3 Drawing Page(s)
LN.CNT 946
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB An improved composition containing peptides and nucleic acids has active components, i.e., which heighten the phagocytic activity f neutrophils, consisting of molecules with a molecular weight of at least 8 kDa, and preferably at least 15 kDa. The active components comprise peptides without aromatic portions and will absorb light at an absorption band of .DELTA..lambda.=200-235 mn, .lambda..sub.max =205 nm, in the UV spectrum. The composition is nontoxic and is formulated using casein, blood albumin, beef peptone, nucleic acid (RNA) and a base such as sodium hydroxide. The composition stimulates phagocytic activity of neutrophils if used at sufficient concentrations. A separate composition is obtained using the same components of manufacture, but filtering or centrifuging the composition to a molecular weight of <8-15 kDa which inhibits phagocytic activity of neutrophils for application in treating auto immune diseases.

L5 ANSWER 18 OF 80 USPATFULL
AN 1998:154280 USPATFULL
TI Methods of treating pulmonary hypertension
IN Gehlert, Donald Richard, Indianapolis, IN, United States
Steinberg, Mitchell Irvin, Indianapolis, IN, United States
PA Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)
PI US 5846973 19981208
AI US 1997-862709 19970523 (8)
PRAI US 1996-18266 19960524 (60)
DT Utility
EXNAM Primary Examiner: Jordan, Kimberly
LREP Gaylo, Paul J.; Boone, David E.
CLMN Number of Claims: 2
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 942
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention provides methods of inhibiting pulmonary hypertensive disease which comprise administering to a mammal in need thereof a compound having activity as a tachykinin receptor antagonist.

L5 ANSWER 19 OF 80 USPATFULL
AN 1998:147415 USPATFULL
TI Inhibitors of collagenase-1 and stormelysin-I metalloproteases, pharmaceutical compositions comprising same and methods of their use
IN Campbell, David A., San Mateo, CA, United States
Patel, Dinesh V., Fremont, CA, United States
Xiao, Xiao-Yi, San Diego, CA, United States
PA Affymax Technologies N.V., Greenford, England (non-U.S. corporation)
PI US 5840698 19981124
AI US 1995-549346 19951027 (8)
RLI Continuation-in-part of Ser. No. US 1995-482211, filed on 7 Jun 1995, now abandoned which is a continuation-in-part of Ser. No. US 1994-329420, filed on 27 Oct 1994, now abandoned
DT Utility
EXNAM Primary Examiner: Achutamurthy, Ponnathapura; Assistant Examiner: Ponnaluri, P.
LREP Swiss, Gerald F.; Stevens, Lauren L.
CLMN Number of Claims: 14
ECL Exemplary Claim: 1
DRWN 17 Drawing Figure(s); 13 Drawing Page(s)
LN.CNT 2250
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed are novel inhibitors of collagenase-1 and stromelysin-I metalloproteases. The disclosed inhibitors are mercaptoketone and mercaptoalcohol compounds which are useful in pharmaceutical

compositions and methods for treating or controlling disease states or conditions which involve tissue breakdown, for example, arthropathy, dermatological conditions, bone resorption, inflammatory diseases, and tumor invasion and in the promotion of wound healing.

L5 ANSWER 20 OF 80 USPATFULL
AN 1998:135148 USPATFULL
TI Inhibitors of metalloproteases, pharmaceutical compositions comprising same and methods of their use
IN Campbell, David A., San Mateo, CA, United States
Patel, Dinesh V., Fremont, CA, United States
Xiao, Xiao-Yi, San Diego, CA, United States
PA Affymax Technologies N.V., Greenford, England (non-U.S. corporation)
PI US 5831004 19981103
AI US 1995-549345 19951027 (8)
RLI Continuation-in-part of Ser. No. US 1995-484255, filed on 7 Jun 1995, now abandoned which is a continuation-in-part of Ser. No. US 1994-329420, filed on 27 Oct 1994, now abandoned
DT Utility
EXNAM Primary Examiner: Tsang, Cecilia J.; Assistant Examiner: Delacroix-Muirheid, C.
LREP Swiss, Gerald F.; Stevens, Lauren L.
CLMN Number of Claims: 8
ECL Exemplary Claim: 1
DRWN 17 Drawing Figure(s); 13 Drawing Page(s)
LN.CNT 2313
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed are novel inhibitors of metalloproteases, in particular matrix metalloproteases. The disclosed inhibitors are mercaptoketone and mercaptoalcohol compounds which are useful in pharmaceutical compositions and methods for treating or controlling disease states or conditions which involve tissue breakdown, for example, arthropathy, dermatological conditions, bone resorption, inflammatory diseases, and tumor invasion and in the promotion of wound healing.

L5 ANSWER 21 OF 80 USPATFULL
AN 1998:124684 USPATFULL
TI Antineoplastic use and pharmaceutical compositions containing them
IN Wicnienski, Nancy A., Kalamazoo, MI, United States
Kelly, Robert C., Augusta, MI, United States
Wuts, Peter G. M., Kalamazoo, MI, United States
PA Pharmacia & Upjohn Company, Kalamazoo, MI, United States (U.S. corporation)
PI US 5821363 19981013
WO 9520582 19950803
AI US 1996-676370 19960723 (8)
WO 1995-US551 19950126
19960723 PCT 371 date
19960723 PCT 102(e) date
RLI Continuation-in-part of Ser. No. US 1994-189235, filed on 28 Jan 1994, now abandoned
DT Utility
EXNAM Primary Examiner: Trinh, Ba K.
LREP Jameson, William G.
CLMN Number of Claims: 23
ECL Exemplary Claim: 1,20,22
DRWN No Drawings
LN.CNT 7196
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention provides 7-deoxy-.DELTA..sup.12,13 -iso-taxol of formula (I) which are useful for the treatment of the same cancers for which taxol has been shown active. ##STR1##

L5 ANSWER 22 OF 80 USPATFULL
AN 1998:115719 USPATFULL
TI Sialyl Le.sup.x analogues as inhibitors of cellular adhesion
IN De Frees, Shawn, San Marcos, CA, United States
Gaeta, Federico C. A., Foster City, CA, United States
Gaudino, John J., Westlake Village, CA, United States
Zheng, Zhongli, Lexington, MA, United States
Hayashi, Masaji, Kobe, Japan
PA Cytel Corporation, San Diego, CA, United States (U.S. corporation)
PI US 5811404 19980922
AI US 4854535 19950607 (8)
RLI Continuation-in-part of Ser. No. 345072, filed on 28 Nov 1994, now patented, Pat. No. 5604207 which is a continuation-in-part of Ser. No. 241645, filed on 12 May 1994 which is a continuation-in-part of Ser. No. 62120, filed on 14 May 1993, now abandoned
DT Utility
EXNAM Primary Examiner: Fonda, Kathleen K.
LREP Townsend and Townsend and Crew
CLMN Number of Claims: 5
ECL Exemplary Claim: 4
DRWN No Drawings
LN.CNT 2846
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to analogues of sialyl Le.sup.x the inhibit cellular adhesion between a selectin and cell that express sialyl Le.sup.x on their surfaces, as well as methods and compositions using the same, intermediates and methods for the preparation of the celluar adhesion inhibitor compounds and their intermediates. A contemplated intermediate or inhibitor compound has a structure that corresponds to that of Formula A, ##STR1## wherein: Z is selected from the group consisting of hydrogen, C.sub.1 -C.sub.6 acyl and ##STR2##

L5 ANSWER 23 OF 80 USPATFULL
AN 1998:111961 USPATFULL
TI Method for selectively reducing activated leukocyte cell population
IN Leong, Simon, Vancouver, Canada
PA Quadra Logic Technologies, Inc., Vancouver, Canada (non-U.S. corporation)
University of British Columbia, Vancouver, Canada (non-U.S. corporation)
PI US 5807881 19980915
AI US 1994-309509 19940922 (8)
RLI Continuation-in-part of Ser. No. US 1992-889707, filed on 27 May 1992
DT Utility
EXNAM Primary Examiner: Burn, Brian M.
LREP Morrison & Foerster
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN 21 Drawing Figure(s); 9 Drawing Page(s)
LN.CNT 1016
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Multiple sclerosis and **rheumatoid arthritis** can be treated effectively using photodynamic therapy. In this protocol, a photoactive compound is administered, allowed to distribute in the effected subject, and the subject is then irradiated to activate the photoactive compound. Alternatively, the blood of a subject to be treated can be subjected to PDT extracorporeally. In the case of **rheumatoid arthritis**, localized treatment at the joints may also be employed.

L5 ANSWER 24 OF 80 USPATFULL
AN 1998:82754 USPATFULL
TI Morpholine compounds are prodrugs useful as tachykinin receptor antagonists
IN Dorn, Conrad P., Plainfield, NJ, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 5780467 19980714
AI US 1997-907738 19970808 (8)
RLI Division of Ser. No. US 1995-525870, filed on 8 Sep 1995, now patented, Pat. No. US 5691336 which is a continuation-in-part of Ser. No. US 1994-206771, filed on 4 Mar 1994, now abandoned
DT Utility
EXNAM Primary Examiner: Higel, Floyd D.
LREP Thies, J. Eric; Rose, David L.
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 7260
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Substituted heterocycles of the general structural formula: ##STR1## are tachykinin receptor antagonists useful in the treatment of inflammatory diseases, pain or migraine, asthma, and emesis.

L5 ANSWER 25 OF 80 USPATFULL
AN 1998:79203 USPATFULL
TI Selective cell inactivation in blood
IN North, Janice, Vancouver, Canada
PA University of British Columbia, Vancouver, Canada (non-U.S. corporation)
Quadra Logic Technologies Inc., Vancouver, Canada (non-U.S. corporation)
PI US 5776966 19980707
AI US 1992-889707 19920527 (7)
DT Utility
EXNAM Primary Examiner: Raymond, Richard L.; Assistant Examiner: Burn, Brian

M.
LREP Morrison & Foerster
CLMN Number of Claims: 12
ECL Exemplary Claim: 1
DRWN 17 Drawing Figure(s); 5 Drawing Page(s)
LN.CNT 599
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Treatment with a set of porphyrin compounds using a photodynamic therapy approach is able selectively to lower elevated levels of activated leukocytes in a leukocyte population. This is particularly helpful in subjects containing such elevated levels of T-cell subsets, such as HIV-infected subjects.

L5 ANSWER 26 OF 80 USPATFULL
AN 1998:54921 USPATFULL
TI Heterocyclic compounds
IN Hohlweg, Rolf, Kvistgaard, Denmark
PA Novo Nordisk A/S, Bagsvaerd, Denmark (non-U.S. corporation)
PI US 5753678 19980519
AI US 1996-715665 19960918 (8)
PRAI DK 1995-1040 19950919
DK 1995-1041 19950919
DT Utility
EXNAM Primary Examiner: Ivy, C. Warren; Assistant Examiner: Aulakh, Charanjit S.
LREP Zelson, Steve T.; Lambiris, Elias J.
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 934
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to novel N-substituted amino alcohols, amino acids and acid derivatives thereof in which a substituted alkyl chain forms part of the N-substituent or salts thereof, to methods for their preparation, to compositions containing them, and to their use for the clinical treatment of painful, hyperalgesic and/or inflammatory conditions in which C-fibers play a pathophysiological role by eliciting neurogenic pain or inflammation.

L5 ANSWER 27 OF 80 USPATFULL
AN 1998:51585 USPATFULL
TI Sialic acid/fucose based medicaments
IN Dasgupta, Falguni, Alameda, CA, United States
Musser, John Henry, San Carlos, CA, United States
PA Glycomed Incorporated, Alameda, CA, United States (U.S. corporation)
PI US 5750508 19980512
AI US 1993-78949 19930616 (8)
DT Utility
EXNAM Primary Examiner: Fonda, Kathleen K.
LREP Lyon & Lyon
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 8 Drawing Figure(s); 6 Drawing Page(s)
LN.CNT 1254
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds that are synthetically inexpensive to make relative to the naturally occurring selectin ligands and that retain selectin binding activity are described that have a three-dimensionally stable configuration for sialic acid and fucose, or analogs or derivatives of these groups, such that sialic acid and fucose are separated by a non-carbohydrate linker that permits binding between those groups and the selectins, such compounds being represented by the following general structure formula I(a): ##STR1## wherein m and n are independently an integer of from 1 to 5, Y and Z are independently a connecting moiety selected from the group consisting of --CH.sub.2 --, --O--, --S--, --NR'and --NR'R"--(wherein R' and R" are independently H or an alkyl containing 1 to 4 carbon atoms); X is a connecting moiety which is selected from the group consisting of --O--, --S-- and --N--; and --R" may be --R"' or any moiety which does not interfere with the three-dimensional configuration of A or B so as to interfere with selectin binding and is preferably a moiety selected from the group consisting of --OR", --SR", --I, --N.sub.3, and --NR'R", and A is selected from the group consisting of .alpha. and .beta. forms of sialic acid, Kemp's acid. Quinic acid, Glyceric acid, Lactic acid and acetic acid, and esters thereof and B is selected from the group consisting of .alpha. and .beta. forms of L-Fucose and esters and substituted forms thereof wherein one or more of the --OH groups is independently --F, or --NR.sup.IV, R.sup.V wherein R.sup.IV and R.sup.V are independently an alkyl contain 1 to 5 carbons.

L5 ANSWER 28 OF 80 USPATFULL
AN 1998:42474 USPATFULL
TI 1-substituted, 2-substituted 1H-imidazo[4,5-C]quinolin-4-amines
IN Gerster, John F., Woodbury, MN, United States
Crooks, Stephen L., Mahtomedi, MN, United States
Lindstrom, Kyle J., Houlton, WI, United States
PA Minnesota Mining and Manufacturing Company, St. Paul, MN, United States (U.S. corporation)
PI US 5741909 19980421
AI US 1997-789264 19970128 (8)
RLI Division of Ser. No. US 1994-353802, filed on 12 Dec 1994, now patented, Pat. No. US 5605899 which is a division of Ser. No. US 1992-938295, filed on 28 Aug 1992, now patented, Pat. No. US 5389640 which is a continuation-in-part of Ser. No. US 1992-838475, filed on 19 Feb 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-687326, filed on 18 Apr 1991, now abandoned which is a continuation-in-part of Ser. No. US 1991-662926, filed on 1 Mar 1991, now abandoned
DT Utility
EXNAM Primary Examiner: Rotman, Alan L.
LREP Howard, MarySusan; Ringsred, Ted K.; Kirn, Walter N.
CLMN Number of Claims: 2
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2448
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB 1-substituted, 2-substituted 1H-imidazo[4,5-c]-quinolin-4-amines are disclosed. These compounds function as antiviral agents, they induce biosynthesis of interferon, and they inhibit tumor formation in animal models. This invention also provides intermediates for preparing such compounds, pharmaceutical compositions containing such compounds, and pharmacological methods of using such compounds.

L5 ANSWER 29 OF 80 USPATFULL
AN 1998:25212 USPATFULL
TI Peptide derivatives
IN Edwards, Philip Duke, Claymont, DE, United States
Schwartz, John Anthony, Wilmington, DE, United States
Stein, Mark Morris, Wilmington, DE, United States
Trainor, Diane Amy, Glen Mills, PA, United States
Wildonger, Richard Alan, Newark, DE, United States
PA Zeneca Inc., Wilmington, DE, United States (U.S. corporation)
PI US 5726158 19980310
AI US 1995-467333 19950606 (8)
RLI Continuation of Ser. No. US 1990-482617, filed on 21 Feb 1990, now abandoned which is a division of Ser. No. US 1987-5538, filed on 20 Jan 1987, now patented, Pat. No. US 4910190 which is a continuation-in-part of Ser. No. US 1986-821150, filed on 21 Jan 1986, now abandoned
PRAI GB 1985-1522 19850122
GB 1985-1523 19850122
GB 1985-1524 19850122
DT Utility
EXNAM Primary Examiner: Johnson, Jerry D.
LREP Hohenschutz, Liza D.
CLMN Number of Claims: 12
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 5961
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention concerns pharmaceutically useful trifluoromethyl ketone substituted di-, tri- and tetra-peptide derivatives of the formulae Ia, Ib, Ic set out hereinafter, and salts thereof, which are inhibitors of human leukocyte elastase. Also described herein are pharmaceutical compositions containing a peptide derivative and processes and intermediates for use in the manufacture of the peptide derivatives.

L5 ANSWER 30 OF 80 USPATFULL
AN 1998:19825 USPATFULL
TI Process for preparing substituted polyazamacrocycles
IN Lennon, Patrick J., Clayton, MO, United States
Henke, Susan L., Webster Grove, MO, United States
Aston, Karl W., Pacific, MO, United States
PA The Monsanto Company, St. Louis, MO, United States (U.S. corporation)
PI US 5721361 19980224
AI US 1996-665070 19960611 (8)
RLI Continuation of Ser. No. US 1995-486434, filed on 7 Jun 1995, now

abandoned
DT Utility
EXNAM Primary Examiner: Shah, Mukund J.; Assistant Examiner: Sripada, Pavanaram K.
LREP Roth, Michael J.; Williams, Roger A.
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2348
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A process for preparing a substituted polyazamacrocycle is provided which comprises contacting a diamine or triamine and a dicarboxylic acid or ester or anhydride thereof in the presence of a suitable base and a suitable solvent to produce the substituted polyazamacrocycle provided that when an ester of said dicarboxylic acid is used, said suitable base is optional, and when said dicarboxylic acid or an anhydride of said dicarboxylic acid is used, the reaction mixture further comprises a suitable coupling agent.

L5 ANSWER 31 OF 80 USPATFULL
AN 1998:17310 USPATFULL
TI Morpholine and thiomorpholine tachykinin receptor antagonists
IN Dorn, Conrad P., Plainfield, NJ, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 5719147 19980217
AI US 1995-525259 19950908 (8)
RLI Continuation-in-part of Ser. No. US 1993-169889, filed on 17 Dec 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-61914, filed on 19 May 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-971448, filed on 4 Nov 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-905976, filed on 29 Jun 1992, now abandoned
DT Utility
EXNAM Primary Examiner: Grumbling, Matthew V.
LREP Thies, J. Eric; Rose, David L.
CLMN Number of Claims: 27
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 8352
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Substituted heterocycles of the general structural formula: ##STR1## are tachykinin receptor antagonists useful in the treatment of inflammatory diseases, pain or migraine, asthma and emesis, and calcium channel blockers useful in the treatment of cardiovascular conditions such as angina, hypertension or ischemia.

L5 ANSWER 32 OF 80 USPATFULL
AN 1998:14789 USPATFULL
TI Treatment of migraine with morpholine tachykinin receptor antagonists
IN Dorn, Conrad P., Plainfield, NJ, United States
MacCoss, Malcolm, Freehold, NJ, United States
Hale, Jeffrey J., Westfield, NJ, United States
Mills, Sander G., Woodbridge, NJ, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 5716942 19980210
AI US 1995-450198 19950525 (8)
RLI Division of Ser. No. US 1994-206771, filed on 4 Mar 1994, now abandoned
DT Utility
EXNAM Primary Examiner: Jarvis, William R. A.
LREP Thies, J. Eric; Rose, David L.
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 6755
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Substituted heterocycles of the general structural formula: ##STR1## are tachykinin receptor antagonists useful in the treatment of inflammatory diseases, pain or migraine, asthma, emesis and nausea.

L5 ANSWER 33 OF 80 USPATFULL
AN 1998:12025 USPATFULL
TI .alpha.-(1,3-dicarbonylenol ether) methyl ketones as cysteine protease inhibitors
IN Zimmerman, Mary P., Pleasonton, CA, United States
Smith, Robert E., Livermore, CA, United States
Becker, Mark, Walnut Creek, CA, United States
PA Prototek, Inc., Dublin, CA, United States (U.S. corporation)
PI US 5714484 19980203
AI US 1995-481808 19950607 (8)
RLI Continuation-in-part of Ser. No. US 1993-164031, filed on 8 Dec 1993, now patented, Pat. No. US 5486623
DT Utility
EXNAM Primary Examiner: Shah, Mukuno J.; Assistant Examiner: Ngo, Tamthom T.
LREP Woodard, Emhardt, Naughton, Moriarty & McNett
CLMN Number of Claims: 3
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1647
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Cysteine protease inhibitors which deactivate the protease by covalently bonding to the cysteine protease and releasing the enolate of a 1,3-dicarbonyl (or its enolic form). The cysteine protease inhibitors of the present invention accordingly comprise a first portion which targets a desired cysteine protease and positions the inhibitor near the thiolate anion portion of the active site of the protease, and a second portion which covalently bonds to the cysteine protease and irreversibly deactivates that protease by providing a carbonyl or carbonyl-equivalent which is attacked by the thiolate anion of the active site of the cysteine protease to sequentially cleave a .beta.-dicarbonyl enol ether leaving group.

L5 ANSWER 34 OF 80 USPATFULL
AN 1998:4236 USPATFULL
TI Receptors for fibroblast growth factors
IN Williams, Lewis T., San Francisco, CA, United States
Johnson, Daniel E., San Francisco, CA, United States
Lee, Pauline E., San Diego, CA, United States
PA The Regents of the University of CA, Alameda, CA, United States (U.S. corporation)
PI US 5707632 19980113
AI US 1995-458938 19950602 (8)
RLI Continuation of Ser. No. US 1992-834311, filed on 13 Feb 1992 which is a continuation-in-part of Ser. No. US 1989-377003, filed on 6 Jul 1989, now abandoned
DT Utility
EXNAM Primary Examiner: Chan, Christina Y.; Assistant Examiner: Nolan, Patrick T.
LREP Townsend and Townsend and Crew LLP
CLMN Number of Claims: 14
ECL Exemplary Claim: 1
DRWN 25 Drawing Figure(s); 17 Drawing Page(s)
LN.CNT 2178
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A fibroblast growth factor (FGF) receptor including a basic fibroblast growth factor receptor has been purified. Various forms have been identified including soluble forms lacking any transmembrane segment. DNA sequences encoding full-length fibroblast growth factor receptors and polypeptides comprising a portion of an FGF-R ligand-binding domain have been isolated and sequenced. These DNAs include DNAs encoding for a basic FGF-R and a human FGF-R and are operably linked to control sequences and expressed in a culture of a compatible host transformed, transfected or electrophoresed by a cloning vehicle containing the DNA sequence. The invention also comprises antibodies to the receptor, methods of synthesizing the growth factor receptor proteins, methods for providing analogs of the fibroblast growth factor receptors. Methods for evaluating compositions which promote or inhibit fibroblastic growth factors and compositions which are agonistic or antagonistic to fibroblast growth factor receptors are also provided. Diagnostic and therapeutic uses are described.

L5 ANSWER 35 OF 80 USPATFULL
AN 97:112623 USPATFULL
TI Phosphonate nucleoside analogs
IN Kim, Choung Un, Madison, CT, United States
Martin, John C., San Carlos, CA, United States
Luh, Bing Uh, Killingworth, CT, United States
Misco, Peter F., Durham, CT, United States
PA Institute of Organic Chemistry and Biochemistry of the Academy of Sciences of the Czech Republic, Czech Republic (non-U.S. corporation)
Rega Stichting v.z.w, Belgium (non-U.S. corporation)
PI US 5693798 19971202
AI US 1995-488337 19950607 (8)
RLI Division of Ser. No. US 1995-391312, filed on 17 Feb 1995 which is a continuation of Ser. No. US 1991-765774, filed on 26 Sep 1991, now abandoned which is a continuation-in-part of Ser. No. US 1990-481569,

filed on 22 Feb 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-352303, filed on 15 May 1989, now abandoned
DT Utility
EXNAM Primary Examiner: Berch, Mark L.
LREP Hensley, Max D.
CLMN Number of Claims: 4
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2641
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Provided are compounds of the following formulae:

A phosphonomethoxymethyoxymethyl purine/pyrimidine derivative of the formula ##STR1## wherein X and X' are the same or different and are hydrogen or alkyl. R and R' are the same or different and are hydrogen, alkyl, hydroxyalkyl or alkanoyl and

B is a purine or pyrimidine base.

A 4'-phosphonomethoxytetrahydrofuranyl-1'-purine-pyrimidine of the formula ##STR2## wherein X and X' are the same or different and are hydrogen or alkyl, Y and Z are the same or different and are hydrogen, hydroxyl or alkyl or Y+Z is an alkenyl, an epoxide or cyclopropyl, and

B is a purine or pyrimidine base.

L5 ANSWER 36 OF 80 USPATFULL
AN 97:109895 USPATFULL
TI Morpholine compounds are prodrugs useful as tachykinin receptor antagonists
IN Dorn, Conrad P., Plainfield, NJ, United States
Hale, Jeffrey J., Westfield, NJ, United States
Maccoss, Malcolm, Freehold, NJ, United States
Mills, Sander G., Woodbridge, NJ, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 5691336 19971125
AI US 1995-525870 19950908 (8)
RLI Continuation-in-part of Ser. No. US 1994-206771, filed on 4 Mar 1994, now abandoned
DT Utility
EXNAM Primary Examiner: Higel, Floyd D.
LREP Thies, J. Eric; Rose, David L.
CLMN Number of Claims: 25
ECL Exemplary Claim: 1,24
DRWN No Drawings
LN.CNT 7292
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Substituted heterocycles of the general structural formula: ##STR1## are tachykinin receptor antagonists useful in the treatment of inflammatory diseases, pain or migraine, asthma, and emesis.

L5 ANSWER 37 OF 80 USPATFULL
AN 97:104632 USPATFULL
TI Nucleoside analogs
IN Kim, Choung Un, Madison, CT, United States
Martin, John C., San Carlos, CA, United States
Luh, Bing Uh, Killingworth, CT, United States
Misco, Peter F., Durham, CT, United States
PA Institute of Organic Chemistry and Biochemistry of the Academy of Sciences of the Czech Republic, Czech Republic (non-U.S. government)
Rega Stichting v.z.w., Belgium (non-U.S. corporation)
PI US 5686611 19971111
AI US 1995-488339 19950607 (8)
RLI Division of Ser. No. US 1995-391312, filed on 17 Feb 1995 which is a continuation of Ser. No. US 1991-765774, filed on 26 Sep 1991, now abandoned which is a continuation-in-part of Ser. No. US 1990-481569, filed on 22 Feb 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-352303, filed on 15 May 1989, now abandoned
DT Utility
EXNAM Primary Examiner: Berch, Mark L.
LREP Hensley, Max D.
CLMN Number of Claims: 5
ECL Exemplary Claim: 1,2
DRWN No Drawings
LN.CNT 2646
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Provided are compounds of the following formulae: A phosphonomethoxymethyoxymethyl purine/pyrimidine derivative of the formula ##STR1## wherein X and X' are the same or different and are hydrogen or alkyl. R and R' are the same or different and are hydrogen, alkyl, hydroxyalkyl or alkanoyl and

B is a purine or pyrimidine base.

A compound of formula (VI) ##STR2## wherein X is halogen, Y is S-phenyl, Se-phenyl or halogen and B is hypoxanthine, xanthine, guanine, 8-bromoguanine, 8-chloroguanine, 8-methylguanine, 8-thioguanine, 3-deazaguanine, purine, 2-aminopurine, 2,6-diaminopurine, adenine, 3-deazaadenine, 8-aminoguanine, 8-hydrazinoguanine, 8-hydroxyguanine, cytosine, 5-ethylcytosine, 5-methylcytosine, thymine, uracil, 5-chlorouracil, 5-bromouracil, 5-ethyluracil, 5-iodouracil, 5-propyluracil or 5-vinyluracil, 2-acetamido-6-diphenylcarbamoylpurine, 6-N-dimethylamino-methyladenine or 6-N-pivaloyladenine.

A compound of formula (VII) ##STR3## wherein B is guanine, 8-guanine, 8-bromoguanine, 8-chloroguanine, 8-methylguanine, 8-thioguanine, 3-deazaguanine, 8-aminoguanine, 8-hydrazinoguanine, 8-hydroxyguanine, cytosine, 5-ethylcytosine, or 5-methylcytosine.

L5 ANSWER 38 OF 80 USPATFULL
AN 97:96530 USPATFULL
TI Sialic acid/fucose based medicaments
IN Dasgupta, Falguni, Alameda, CA, United States
Musser, John Henry, San Carlos, CA, United States
PA Glycomed Incorporated, Alameda, CA, United States (U.S. corporation)
PI US 5679321 19971021
AI US 1995-468788 19950606 (8)
RLI Division of Ser. No. US 1993-78948, filed on 17 Jun 1993, now abandoned
DT Utility
EXNAM Primary Examiner: Hutzell, Paula K.; Assistant Examiner: Minnifield, N. M.
LREP Lyon & Lyon LLP
CLMN Number of Claims: 11
ECL Exemplary Claim: 1
DRWN 7 Drawing Figure(s); 7 Drawing Page(s)
LN.CNT 1199
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds that are synthetically inexpensive to make relative to the naturally occurring selectin ligands and that retain selectin binding activity are described that have a three-dimensionally stable configuration for sialic acid and fucose, or analogs or derivatives of these groups, such that sialic acid and fucose are separated by a non-carbohydrate linker that permits binding between those groups and the selectins, such compounds being represented by the following general structural formula I(a): ##STR1## wherein m and n are independently an integer of from 1 to 5, Y and Z are independently a connecting moiety selected from the group consisting of --CH.sub.2 --, --O--, --S--, --NR' and --NR'R"-- (wherein R' and R" are independently H or an alkyl containing 1 to 4 carbon atoms); X is a connecting moiety which is selected from the group consisting of --O--, --S-- and --N--; and --R'" may be --R" or any moiety which does not interfere with the three-dimensional configuration of A or B so as to interfere with selectin binding and is preferably a moiety selected from the group consisting of --OR", --SR", --I, --N.sub.3, and --NR'R", and A is selected from the group consisting of .alpha. and .beta. forms of sialic acid, Kemp's acid, Quinic acid, Glyceric acid, Lactic acid and acetic acid, and esters thereof and B is selected from the group consisting of .alpha. and .beta. forms of L-Fucose and esters and substituted forms thereof wherein one or more of the --OH groups is independently --F, or --NR.sup.IV, R.sup.V wherein R.sup.IV and R.sup.V are independently an alkyl contain 1 to 5 carbons.

L5 ANSWER 39 OF 80 USPATFULL
AN 97:75978 USPATFULL
TI Sialic acid/fucose based assay reagents and assay methods
IN Dasgupta, Falguni, Alameda, CA, United States
Musser, John Henry, San Carlos, CA, United States
PA Glycomed Incorporated, Alameda, CA, United States (U.S. corporation)
PI US 5660992 19970826
AI US 1995-464507 19950605 (8)
RLI Division of Ser. No. US 1993-78949, filed on 16 Jun 1993, now abandoned
DT Utility
EXNAM Primary Examiner: Hutzell, Paula K.; Assistant Examiner: Minnifield, N. M.
LREP Lyon & Lyon LLP
CLMN Number of Claims: 20

ECL Exemplary Claim: 1
DRWN 8 Drawing Figure(s); 6 Drawing Page(s)
LN.CNT 1262
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds that are synthetically inexpensive to make relative to the naturally occurring selectin ligands and that retain selectin binding activity are described that have a three-dimensionally stable configuration for sialic acid and fucose, or analogs or derivatives of these groups, such that sialic acid and fucose are separated by a non-carbohydrate linker that permits binding between those groups and the selectins, such compounds being represented by the following general structural formula I(a): ##STR1## wherein m and n are independently an integer of from 1 to 5, Y and Z are independently a connecting moiety selected from the group consisting of --CH.sub.2 --, --O--, --S--, --NR' and --NR'R"-- (wherein R' and R" are independently H or an alkyl containing 1 to 4 carbon atoms); X is a connecting moiety which is selected from the group consisting of --O--, --S--and --N--; and --R"' may be --R" or any moiety which does not interfere with the three-dimensional configuration of A or B so as to interfere with selectin binding and is preferably a moiety selected from the group consisting of --OR", --SR", --I, --N.sub.3, and --NR'R" and A is selected from the group consisting of .alpha. and .beta. forms of sialic acid, Kemp's acid, Quinic acid, Glyceric acid, Lactic acid and acetic acid, and esters thereof and B is selected from the group consisting of .alpha. and .beta. forms of L-Fucose and esters and substituted forms thereof wherein one or more of the --OH groups is independently --F, or --NR.sup.IV, R.sup.V wherein R.sup.IV and R.sup.V are independently an alkyl contain 1 to 5 carbons.

L5 ANSWER 40 OF 80 USPATFULL
AN 97:73587 USPATFULL
TI Sialic acid/fucose based medicaments
IN Dasgupta, Falguni, San Leandro, CA, United States
Musser, John H., San Carlos, CA, United States
Levy, Daniel E., Oakland, CA, United States
Tang, Peng Cho, Moraga, CA, United States
PA Glycomed Incorporated, Alameda, CA, United States (U.S. corporation)
PI US 5658880 19970819
AI US 1994-289715 19940812 (8)
RLI Continuation-in-part of Ser. No. US 1993-78949, filed on 16 Jun 1993, now abandoned
DT Utility
EXNAM Primary Examiner: Kunz, Gary L.; Assistant Examiner: Fonda, Kathleen Kahler
LREP Lyon & Lyon
CLMN Number of Claims: 48
ECL Exemplary Claim: 1
DRWN 8 Drawing Figure(s); 6 Drawing Page(s)
LN.CNT 2200
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds that exhibit selectin binding activity are described and have the following structural formula: ##STR1## where W is selected from a group including structures a-d below ##STR2## wherein p is an integer of from 0-2, q is an integer of from 0-3, and r is an integer of from 0-5; A is selected from the group consisting of .alpha. and .beta. forms of sialic acid, Kemp's acid, quinic acid, R and S forms of mandelic acid, R and S forms of glyceric acid, R and S forms of lactic acid, propionic and acetic acid, and esters and amides thereof, --SO.sub.3, sulfonate, --PO.sub.3, phosphonate, trifluoromethyl, diazine and triazine; is selected from a group consisting of .alpha. and .beta. forms of fucose, arabinose and esters and substituted forms thereof wherein one or more of the OH groups is independently substituted with F, N.sub.3, NHAc, NHCOCF.sub.3. The remaining variable are described in the specification.

L5 ANSWER 41 OF 80 USPATFULL
AN 97:61681 USPATFULL
TI PLA.sub.2 inhibitors
IN Lennon, Patrick James, Clayton, MO, United States
PA Monsanto Company, St. Louis, MO, United States (U.S. corporation)
PI US 5648349 19970715
AI US 1995-430054 19950427 (8)
RLI Division of Ser. No. US 1994-259720, filed on 14 Jun 1994, now patented, Pat. No. US 5434288 which is a continuation-in-part of Ser. No. US 1992-984022, filed on 1 Dec 1992, now abandoned
DT Utility
EXNAM Primary Examiner: Richter, Johann; Assistant Examiner: Ambrose, Michael G.
LREP Fitzpatrick, Cella, Harper & Scinto
CLMN Number of Claims: 13
ECL Exemplary Claim: 1,13
DRWN No Drawings
LN.CNT 1080
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB PLA.sub.2 inhibitors selected from the group consisting of ##STR1## wherein A is selected from the group consisting of ##STR2## and Z, W, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8, R.sub.9, X, X' and Y are as defined herein.

L5 ANSWER 42 OF 80 USPATFULL
AN 97:49744 USPATFULL
TI Process for preparing morpholine tachykinin receptor antagonists
IN Dorn, Conrad P., Plainfield, NJ, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 5637699 19970610
AI US 1995-445489 19950522 (8)
RLI Division of Ser. No. US 1993-169889, filed on 17 Dec 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-61914, filed on 19 May 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-971448, filed on 4 Nov 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-905976, filed on 29 Jun 1992, now abandoned
DT Utility
EXNAM Primary Examiner: Grumbling, Matthew V.
LREP Thies, J. Eric; Rose, David L.
CLMN Number of Claims: 2
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 6269
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Substituted heterocycles of the general structural formula: ##STR1## are tachykinin receptor antagonists useful in the treatment of inflammatory diseases, pain or migraine, asthma and emesis, and calcium channel blockers useful in the treatment of cardiovascular conditions such as angina, hypertension or ischemia.

L5 ANSWER 43 OF 80 USPATFULL
AN 97:17918 USPATFULL
TI Compositions and methods for enhanced drug delivery
IN Hale, Ron L., Woodside, CA, United States
Lu, Amy, Los Altos, CA, United States
Solas, Dennis, San Francisco, CA, United States
Selick, Harold E., Belmont, CA, United States
Oldenburg, Kevin R., Fremont, CA, United States
Zaffaroni, Alejandro C., Atherton, CA, United States
PA Affymax Technologies N.V., Middlesex, England (non-U.S. corporation)
PI US 5607691 19970304
AI US 1995-449188 19950524 (8)
RLI Continuation of Ser. No. US 1993-164293, filed on 9 Dec 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-77296, filed on 14 Jun 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-898219, filed on 12 Jun 1992, now abandoned And a continuation-in-part of Ser. No. US 1993-9463, filed on 27 Jan 1993, now abandoned
DT Utility
EXNAM Primary Examiner: Levy, Neil S.
LREP Stevens, Lauren L.
CLMN Number of Claims: 5
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 5349
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to methods of delivering pharmaceutical agents across membranes, including the skin layer or mucosal membranes of a patient. A pharmaceutical agent is covalently bonded to a chemical modifier, via a physiologically cleavable bond, such that the membrane transport and delivery of the agent is enhanced.

L5 ANSWER 44 OF 80 USPATFULL
AN 97:16054 USPATFULL
TI 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
IN Gerster, John F., Woodbury, MN, United States
Crooks, Stephen L., Mahtomedi, MN, United States
Lindstrom, Kyle J., Houlton, WI, United States
PA Minnesota Mining and Manufacturing Company, St. Paul, MN, United States

(U.S. corporation)
PI US 5605899 19970225
AI US 1994-353802 19941212 (8)
RLI Division of Ser. No. US 1992-938295, filed on 28 Aug 1992, now patented, Pat. No. US 5389640 which is a continuation-in-part of Ser. No. US 1992-838475, filed on 19 Feb 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-687326, filed on 18 Apr 1991, now abandoned which is a continuation-in-part of Ser. No. US 1991-662926, filed on 1 Mar 1991, now abandoned
DT Utility
EXNAM Primary Examiner: Rotman, Alan L.
LREP Griswold, Gary L.; Kirn, Walter N.; Ringsred, Ted K.
CLMN Number of Claims: 36
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2585
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB 1-substituted, 2-substituted 1H-imidazo[4,5-c]-quinolin-4-amines are disclosed. These compounds function as antiviral agents, they induce biosynthesis of interferon, and they inhibit tumor formation in animal models. This invention also provides intermediates for preparing such compounds, pharmaceutical compositions containing such compounds, and pharmacological methods of using such compounds.

L5 ANSWER 45 OF 80 USPATFULL
AN 97:14683 USPATFULL
TI Sialyl Le.sup.x analogues as inhibitors of cellular adhesion
IN DeFrees, Shawn A., San Marcos, CA, United States
Gaeta, Federico C. A., Olivenhain, CA, United States
Gaudino, John J., Westlake Village, CA, United States
Zheng, Zhongli, Lexington, MA, United States
Hayashi, Masaji, Kobe, Japan
PA Cytel Corporation, San Diego, CA, United States (U.S. corporation)
PI US 5604207 19970218
AI US 1994-345072 19941128 (8)
RLI Continuation-in-part of Ser. No. US 1994-241645, filed on 12 May 1994 which is a continuation-in-part of Ser. No. US 1993-62120, filed on 14 May 1993, now abandoned
DT Utility
EXNAM Primary Examiner: Kunz, Gary L.; Assistant Examiner: Fonda, Kathleen Kahler
LREP Townsend and Townsend and Crew
CLMN Number of Claims: 44
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3352
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The inventive compounds are analogues of sialyl Le.sup.x that inhibit cellular adhesion between a selectin and cells that express sialyl Le.sup.x on their surfaces, and their synthetic intermediates. An inventive compound has structure A, ##STR1## wherein Z is hydrogen, C.sub.1 -C.sub.6 acyl or ##STR2## Y is C(O), SO.sub.2, HNC(O), OC(O) or SC(O); R.sup.1 is an aryl, a substituted aryl or a phenyl C.sub.1 -C.sub.3 alkylene group, wherein an aryl group has one five- or six-membered aromatic ring, a fused five/six-membered aromatic ring, or two fused six-membered aromatic rings, which rings are hydrocarbyl, monooxahydrocarbyl, monothiahydrocarbyl, monoazahydrocarbyl or diazahydrocarbyl rings, and a substituted aryl group is an aryl group having a halo, trifluoromethyl, nitro, C.sub.1 -C.sub.18 alkyl, C.sub.1 -C.sub.18 alkoxy, amino, mono-C.sub.1 -C.sub.18 alkylamino, di-C.sub.1 -C.sub.18 alkylamino, benzylamino, C.sub.1 -C.sub.18 alkylbenzylamino, C.sub.1 -C.sub.18 thioalkyl or C.sub.1 -C.sub.18 alkyl carboxamido substituent, or

R.sup.1 Y is allyloxycarbonyl or chloroacetyl;

R.sup.2 is hydrogen, C.sub.1 -C.sub.18 straight chain, branched chain or cyclic hydrocarbyl, C.sub.1 -C.sub.6 alkyl C.sub.1 -C.sub.5 alkylene .omega.-carboxylate, .omega.-tri(C.sub.1 -C.sub.4 alkyl/phenyl)silyl C.sub.2 -C.sub.4 alkylene, monosaccharide or disaccharide,

or OR.sup.2 together form a C.sub.1 -C.sub.18 straight chain, branched chain or cyclic hydrocarbyl carbamate;

R.sup.3 is hydrogen or C.sub.1 -C.sub.6 acyl;

R.sup.4 is hydrogen, C.sub.1 -C.sub.6 alkyl or benzyl;

R.sup.5 is hydrogen, benzyl, methoxybenzyl, dimethoxybenzyl or C.sub.1 -C.sub.6 acyl;

R.sup.7 is methyl or hydroxymethyl; and

X is C.sub.1 -C.sub.6 acyloxy, C.sub.2 -C.sub.6 hydroxylacyloxy, hydroxy, halo or azido.

L5 ANSWER 46 OF 80 USPATFULL
AN 96:55766 USPATFULL
TI Bis-piperidinyl non-peptidyl neurokinin receptor antagonists
IN Cho, Sung Yong S., Indianapolis, IN, United States
PA Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)
PI US 5530009 19960625
AI US 1996-462413 19960605 (8)
RLI Division of Ser. No. US 1994-271708, filed on 12 Jul 1994
DT Utility
EXNAM Primary Examiner: Chang, Ceila
LREP Gaylo, Paul J.; Boone, David E.
CLMN Number of Claims: 3
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1027
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention provides novel compound of the formula ##STR1## which is neurokinin receptor antagonist.

L5 ANSWER 47 OF 80 USPATFULL
AN 96:46037 USPATFULL
TI Heterocyclic amides
IN Bernstein, Peter R., Wallingford, PA, United States
Shaw, Andrew, Kennett Square, PA, United States
Thomas, Royston M., Macclesfield, England
Warner, Peter, Macclesfield, England
Wolanin, Donald J., Orange, CT, United States
PA Zeneca Limited, London, England (non-U.S. corporation)
PI US 5521179 19960528
AI US 1993-45009 19930408 (8)
RLI Continuation-in-part of Ser. No. US 1992-869993, filed on 16 Apr 1992, now abandoned
DT Utility
EXNAM Primary Examiner: Ivy, C. Warren; Assistant Examiner: Compton, Raymond
LREP Alexander, Michael D.; Newtson, Ruth H.; Harris, Robert J.
CLMN Number of Claims: 14
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 7408
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to certain novel heterocyclic amides which are 1-pyridylacetamide compounds of formula I, set out herein, which are inhibitors of human leukocyte elastase (HLE), also known as human neutrophil elastase (HNE), making them useful whenever such inhibition is desired, such as for research tools in pharmacological, diagnostic and related studies and in the treatment of diseases in mammals in which HLE is implicated. The invention also includes intermediates useful in the synthesis of these heterocyclic amides, processes for preparing the heterocyclic amides, pharmaceutical compositions containing such heterocyclic amides and methods for their use.

L5 ANSWER 48 OF 80 USPATFULL
AN 96:36566 USPATFULL
TI Treatment of emesis with morpholine tachykinin receptor antagonists
IN Dorn, Conrad P., Plainfield, NJ, United States
MacCoss, Malcolm, Freehold, NJ, United States
Hale, Jeffrey J., Westfield, NJ, United States
Mills, Sander G., Woodbridge, NJ, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 5512570 19960430
AI US 1995-450507 19950525 (8)
RLI Division of Ser. No. US 1994-206771, filed on 4 Mar 1994
DT Utility
EXNAM Primary Examiner: Higel, Floyd D.
LREP Thies, J. Eric; Rose, David L.
CLMN Number of Claims: 15
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 6501
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Substituted heterocycles of the structural formula: ##STR1## are tachykinin receptor antagonists useful in the treatment of inflammatory diseases, pain or migraine, asthma, emesis and nausea.

L5 ANSWER 49 OF 80 USPATFULL
AN 96:27346 USPATFULL

TI PLA.sub.2 inhibitors
IN Lennon, Patrick J., Clayton, MO, United States
PA Monsanto Company, St. Louis, MO, United States (U.S. corporation)
PI US 5504237 19960402
AI US 1995-429972 19950427 (8)
RLI Division of Ser. No. US 1994-259720, filed on 14 Jun 1994, now patented, Pat. No. US 5434288 which is a continuation-in-part of Ser. No. US 1992-984022, filed on 1 Dec 1992, now abandoned
DT Utility
EXNAM Primary Examiner: Richter, Johann; Assistant Examiner: Ambrose, Michael
G.
LREP Goetz, Kenneth D.
CLMN Number of Claims: 19
ECL Exemplary Claim: 1,16
DRWN No Drawings
LN.CNT 1050
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB PIA.sub.2 inhibitors selected from the group consisting of ##STR1## wherein A is selected from the group consisting of ##STR2## and Z, W, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8, R.sub.9, X, X' and Y are as defined herein.

L5 ANSWER 50 OF 80 USPATFULL
AN 95:84401 USPATFULL
TI Halogenated phenylacetonitrile alkylaminoalkylphenyl compounds as immunosuppressives
IN Mueller, Richard A., Glencoe, IL, United States
PA G. D. Searle & Co., Chicago, IL, United States (U.S. corporation)
PI US 5451604 19950919
AI US 1993-97809 19930726 (8)
DT Utility
EXNAM Primary Examiner: Brust, Joseph Paul
LREP Keane, J. Timothy
CLMN Number of Claims: 4
ECL Exemplary Claim: 3
DRWN No Drawings
LN.CNT 5690
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A class of halogenated phenylacetonitrile alkylaminoalkylphenyl compounds having immunosuppressive properties is described. Compounds of this class would be useful in reducing recipient rejection of transplanted organs and for treatment of autoimmune or inflammatory diseases. Compounds of particular interest are of the formula ##STR1## wherein m is a number selected from three to five, inclusive; wherein n one or two; wherein R.sup.1 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, iso-butyl, n-pentyl, isopentyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl, benzyl and phenethyl; wherein R.sup.2 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, iso-butyl, n-pentyl, isopentyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl, benzyl and phenethyl; wherein each of R.sup.3 through R.sup.7 is selected from hydrido, fluoro, chloro, bromo, azide, trifluoromethyl, difluorochloromethyl, 1,1-difluoroethyl, 2,2,2-trifluoroethyl, perfluoroethyl and 2,2,2,3-tetrafluoropropyl; with the proviso that at least one of R.sup.3 through R.sup.7 is selected from fluoro and trifluoromethyl; or a tautomer thereof or a pharmaceutically-acceptable salt thereof.

L5 ANSWER 51 OF 80 USPATFULL
AN 95:65056 USPATFULL
TI PLA.sub.2 inhibitors
IN Lennon, Patrick J., Clayton, MO, United States
PA Monsanto Company, St. Louis, MO, United States (U.S. corporation)
PI US 5434288 19950718
AI US 1994-259720 19940614 (8)
RLI Continuation-in-part of Ser. No. US 1992-984022, filed on 1 Dec 1992, now abandoned
DT Utility
EXNAM Primary Examiner: Ramsuer, Robert W.; Assistant Examiner: Ambrose, Michael G.
LREP Goetz, Kenneth D.; Passley, Paul L.; Bolding, James C.
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1031
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB PLA.sub.2 inhibitors selected from the group consisting of ##STR1## wherein A is selected from the group consisting of ##STR2## and Z, W, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8, R.sub.9, X, X' and Y are as defined herein.

L5 ANSWER 52 OF 80 USPATFULL
AN 95:41068 USPATFULL
TI 1-alkyl-2-hydroxy-2-trifluoromethyl ethylamines
IN Stein, Mark M., Wilmington, DE, United States
Trainor, Diane A., Glen Mills, PA, United States
PA Zeneca Inc., Wilmington, DE, United States (U.S. corporation)
PI US 5414132 19950509
AI US 1992-940932 19920904 (7)
RLI Division of Ser. No. US 1990-491757, filed on 9 Mar 1990, now patented, Pat. No. US 5194588 which is a division of Ser. No. US 1987-5538, filed on 20 Jan 1987, now patented, Pat. No. US 4910190 which is a continuation-in-part of Ser. No. US 1986-821150, filed on 21 Jan 1986, now abandoned
PRAI GB 1985-1522 19850122
GB 1985-1523 19850122
GB 1985-1524 19850122
DT Utility
EXNAM Primary Examiner: Raymond, Richard L.
LREP Cushman Darby & Cushman
CLMN Number of Claims: 2
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 5536
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention concerns pharmaceutically useful trifluoromethyl ketone substituted di-, tri- and tetra-peptide derivatives of the formulae Ia, Ib, Ic set out hereinafter, and salts thereof, which are inhibitors of human leukocyte elastase. Also described herein are pharmaceutical compositions containing a peptide derivative and processes and intermediates for use in the manufacture of the peptide derivatives.

L5 ANSWER 53 OF 80 USPATFULL
AN 95:13873 USPATFULL
TI 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
IN Gerster, John F., Woodbury, MN, United States
Crooks, Stephen L., Mahtomedi, MN, United States
Lindstrom, Kyle J., Houlton, WI, United States
PA Minnesota Mining and Manufacturing Company, St. Paul, MN, United States (U.S. corporation)
PI US 5389640 19950214
AI US 1992-938295 19920828 (7)
RLI Continuation-in-part of Ser. No. US 1992-838475, filed on 19 Feb 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-687326, filed on 18 Apr 1991, now abandoned which is a continuation-in-part of Ser. No. US 1991-662926, filed on 1 Mar 1991, now abandoned
DT Utility
EXNAM Primary Examiner: Rotman, Alan L.
LREP Griswold, Gary L.; Kirn, Walter N.; Reedich, Douglas E.
CLMN Number of Claims: 15
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2463
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB 1-substituted, 2-substituted 1H-imidazo[4,5-c]-quinolin-4-amines are disclosed. These compounds function as antiviral agents, they induce biosynthesis of interferon, and they inhibit tumor formation in animal models. This invention also provides intermediates for preparing such compounds, pharmaceutical compositions containing such compounds, and pharmacological methods of using such compounds.

L5 ANSWER 54 OF 80 USPATFULL
AN 93:89678 USPATFULL
TI Azabicyclic compounds, pharmaceutical compositions containing them and their use in therapy
IN Ladduwahetty, Tamara, Buckhurst Hill, England
Swain, Christopher J., Duxford, England
PA Merck Sharp & Dohme, Limited, Hoddesdon, England (non-U.S. corporation)
PI US 5256671 19931026
AI US 1992-905974 19920629 (7)
DT Utility
EXNAM Primary Examiner: Tsang, Cecilia

LREP North, Robert J.; Caruso, Charles M.; DiPrima, Joseph F.
CLMN Number of Claims: 12
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1061
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds of formula (I), and salts and prodrugs thereof: ##STR1## wherein Q is the residue of an optionally substituted azabicyclic ring system;
the dotted line represents an optional double bond;
X represents H, --OH, .dbd.O or halo;
R.sup.1 represents H, phenyl or thienyl, which phenyl or thienyl groups may be optionally substituted by halo or trifluoromethyl;
R.sup.2 represents phenyl, thienyl or benzyl, any of which groups may be optionally substituted by halo or trifluoromethyl; and
R.sup.3, R.sup.4 and R.sup.5 independently represent H, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, halo, cyano, nitro, trifluoromethyl, trimethylsilyl, --OR.sup.a, SR.sup.a, SOR.sup.a, SO.sub.2 R.sup.a, --NR.sup.a R.sup.b, --NR.sup.a COR.sup.b, --NR.sup.a CO.sub.2 R.sup.b, --CO.sub.2 R.sup.a or --CONR.sup.a R.sup.b ; and
R.sup.a and R.sup.b independently represent H, C.sub.1-6 alkyl, phenyl or trifluoromethyl, are tachykinin receptor antagonists. They and compositions thereof are useful in therapy.

L5 ANSWER 55 OF 80 USPATFULL
AN 93:82882 USPATFULL
TI Indole-,benzofuran-,and benzothiophene-containing lipoxygenase-inhibiting compounds
IN Brooks, Dee W., Libertyville, IL, United States
Summers, James B., Libertyville, IL, United States
PA Abbott Laboratories, Abbott Park, IL, United States (U.S. corporation)
PI US 5250565 19931005
AI US 1992-823411 19920121 (7)
DCD 20061010
RLI Continuation of Ser. No. US 1990-572451, filed on 28 Aug 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-404300, filed on 7 Sep 1989, now abandoned which is a continuation-in-part of Ser. No. US 1988-138073, filed on 11 Jan 1988, now patented, Pat. No. US 4873259 which is a continuation-in-part of Ser. No. US 1987-60784, filed on 10 Jun 1987, now abandoned which is a continuation-in-part of Ser. No. US 1987-12970, filed on 10 Feb 1987, now abandoned
DT Utility
EXNAM Primary Examiner: Siegel, Alan
LREP Janssen, Jerry F.
CLMN Number of Claims: 3
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 764
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Pro-drugs of potent 5-lipoxygenase inhibiting compounds comprise compounds of the formula ##STR1## in which A is an alkylene or alkenylene group, X is oxygen, sulfur, sulfoxyl, or substituted nitrogen, and Y is a group which includes substituted or unsubstituted carbocyclic or substituted or unsubstituted heterocyclic aryl. R.sup.1 is an alkyl, alkenyl, amino, alkylamino, dialkylamino, or hydroxyamino group or an amine group bearing a metabolically cleavable leaving group. M is hydrogen, a pharmaceutically acceptable cation or a metabolically cleavable leaving group, with the proviso that either M or R.sup.1 must bear a metabolically cleavable leaving group.

L5 ANSWER 56 OF 80 USPATFULL
AN 93:20683 USPATFULL
TI Aminoalcohol intermediates for peptide derivatives
IN Edwards, Philip D., Claymont, DE, United States
PA ICI Americas Inc., Wilmington, DE, United States (U.S. corporation)
PI US 5194588 19930316
AI US 1990-491757 19900309 (7)
RLI Division of Ser. No. US 1987-5538, filed on 20 Jan 1987, now patented, Pat. No. US 4910190 which is a continuation-in-part of Ser. No. US 1986-821150, filed on 21 Jan 1986, now abandoned
PRAI GB 1985-1522 19850122
GB 1985-1523 19850122
GB 1985-1524 19850122
DT Utility
EXNAM Primary Examiner: Lee, Lester L.
LREP Miano, Rosemary M.; Jackson, Thomas E.
CLMN Number of Claims: 7
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 5515
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention concerns pharmaceutically useful trifluoromethyl ketone substituted di-, tri- and tetra-peptide derivatives of the formulae Ia, Ib, Ic set out hereinafter, and salts thereof, which are inhibitors of human leukocyte elastase. Also described herein are pharmaceutical compositions containing a peptide derivative and processes and intermediates for use in the manufacture of the peptide derivatives.

L5 ANSWER 57 OF 80 USPATFULL
AN 92:72472 USPATFULL
TI Halomacrolides and derivatives having immunosuppressive activity
IN Bochis, Richard J., East Brunswick, NJ, United States
Wyvratt, Jr., Matthew J., Mountainside, NJ, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 5143918 19920901
AI US 1991-759747 19910912 (7)
RLI Continuation of Ser. No. US 1990-596177, filed on 11 Oct 1990, now abandoned
DT Utility
EXNAM Primary Examiner: Bond, Robert T.
LREP Caruso, Charles M.; North, Robert J.; Thies, J. Eric
CLMN Number of Claims: 9
ECL Exemplary Claim: 1,9
DRWN No Drawings
LN.CNT 2003
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Novel C-3" and C-4" halogen-substituted macrolides of FK-506 type structural Formula I: ##STR1## are described. These macrolide immunosuppressants are useful in a mammalian host for the treatment of autoimmune diseases (such as juvenile-onset diabetes melitus, multiple sclerosis and **rheumatoid arthritis**), infectious diseases and/or the prevention of rejection of foreign organ transplants, e.g. bone marrow and heart transplants. In addition, these macrolide immunosuppressants are useful in the topical treatment of inflammatory and hyperproliferative skin diseases and cutaneous manifestations of immunologically-mediated illnesses such as: psoriasis, atopical dermatitiis, contact dermatitis and further eczematous dermatitises, seborrhoeic dermatitis, Lichen planus, Pemphigus, bullous Pemphigoid, Epidermolysis bullosa, urticaria, angioedemas, vasulitides erythemas, cutaneous eosinophilias, Lupus erythematosus or Alopecia areata.

L5 ANSWER 58 OF 80 USPATFULL
AN 92:68332 USPATFULL
TI Amine derivatives of folic acid analogs
IN Coughlin, Daniel J., Robbinsville, NJ, United States
Rodwell, John D., Yardley, PA, United States
PA Cytogen Corporation, NJ, United States (U.S. corporation)
PI US 5140104 19920818
AI US 1989-426374 19891024 (7)
RLI Continuation of Ser. No. US 1986-861037, filed on 8 May 1986, now abandoned which is a continuation-in-part of Ser. No. US 1984-650375, filed on 13 Sep 1984, now patented, Pat. No. US 4867973 Ser. No. Ser. No. US 1984-650754, filed on 13 Sep 1984, now abandoned Ser. No. Ser. No. US 1984-646327, filed on 31 Aug 1984, now abandoned Ser. No. Ser. No. US 1984-646328, filed on 31 Aug 1984, now patented, Pat. No. US 4741900 And Ser. No. US 1982-356315, filed on 9 Mar 1982, now patented, Pat. No. US 4671958
DT Utility
EXNAM Primary Examiner: Waddell, Frederick E.; Assistant Examiner: Weddington,
K.
LREP Pennie & Edmonds
CLMN Number of Claims: 10
ECL Exemplary Claim: 1
DRWN 2 Drawing Figure(s); 2 Drawing Page(s)
LN.CNT 1476
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Novel therapeutic antibody conjugates comprising amine derivatives of folic acid analogs covalently attached via a reactive amine group to an oxidized carbohydrate moiety of an antibody or antibody fragment are disclosed. The conjugates retain substantially the same immunorespecificity and immunoreactivity of the unconjugated antibody molecule. The immunospecificity and immunoreactivity of the antibody conjugates permits targeted delivery of the attached therapeutically effective amine derivative of folic acid analogs in vivo. The conjugates

are therapeutically effective against a variety of neoplastic and non-neoplastic cellular disorders when administered in vivo. Methods for synthesizing the amine derivatives of folic acid analogs, methods for preparing the antibody conjugates, and methods for use of the conjugates in vivo are also disclosed.

L5 ANSWER 59 OF 80 USPATFULL
AN 92:59870 USPATFULL
TI Substituted cephalosporin sulfones as anti-inflammatory and anti-degenerative agents
IN Doherty, James B., New Milford, NJ, United States
Firestone, Raymond A., Westfield, NJ, United States
Finke, Paul E., Milltown, NJ, United States
Hagmann, William K., Westfield, NJ, United States
Shah, Shrenik K., Metuchen, NJ, United States
Thompson, Kevan R., Westfield, NJ, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 5132301 19920721
AI US 1990-471320 19900129 (7)
RLI Continuation of Ser. No. US 1986-930193, filed on 12 Nov 1986, now abandoned which is a continuation-in-part of Ser. No. US 1985-774425, filed on 10 Sep 1985, now abandoned which is a continuation-in-part of Ser. No. US 1983-490761, filed on 2 May 1983, now abandoned
DT Utility
EXNAM Primary Examiner: Rizzo, Nicholas S.
LREP Panzer, Curtis C.; Pfeiffer, Hesna J.
CLMN Number of Claims: 6
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2147
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB New substituted cephalosporin sulfones are found to be potent elastase inhibitors and thereby useful anti-inflammatory/antidegenerative agents.

L5 ANSWER 60 OF 80 USPATFULL
AN 91:82198 USPATFULL
TI Peptide derivatives
IN Edwards, Philip D., Claymont, DE, United States
Schwartz, John A., Wilmington, all, DE, United States
Stein, Mark M., Wilmington, all, DE, United States
Trainor, Diane A., Glen Mills, PA, United States
Wildonger, Richard A., Elmwood, DE, United States
PA ICI Americas Inc., Wilmington, DE, United States (U.S. corporation)
PI US 5055450 19911008
AI US 1990-493025 19900313 (7)
RLI Division of Ser. No. US 1987-5538, filed on 20 Jan 1987, now patented, Pat. No. US 4910190 which is a continuation-in-part of Ser. No. US 1986-821150, filed on 21 Jan 1986, now abandoned
PRAI GB 1985-1522 19850122
GB 1985-1523 19850122
GB 1985-5124 19850122
DT Utility
EXNAM Primary Examiner: Lee, Lester L.; Assistant Examiner: Davenport, Avis
LREP Miano, Rosemary M.; Jackson, Thomas E.
CLMN Number of Claims: 7
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 6077
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention concerns pharmaceutically useful trifluoromethyl ketone substituted di-, tri- and tetra-peptide derivatives of the formulae Ia, Ib, Ic set out hereinafter, and salts thereof, which are inhibitors of human leukocyte elastase. Also described herein are pharmaceutical compositions containing a peptide derivative and processes and intermediates for use in the manufacture of the peptide derivatives.

L5 ANSWER 61 OF 80 USPATFULL
AN 91:46724 USPATFULL
TI Substituted 1-H-pyrrolopyridine-3-carboxamides
IN Scherlock, Margaret H., Bloomfield, NJ, United States
Tom, Wing C., Cedar Grove, NJ, United States
PA Schering Corporation, Kenilworth, NJ, United States (U.S. corporation)
PI US 5023265 19910611
AI US 1990-532304 19900601 (7)
DT Utility
EXNAM Primary Examiner: Dentz, Bernard I.
LREP Nelson, James R.
CLMN Number of Claims: 11
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 755
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Substituted 1H-pyrrolopyridine-3-carboxamides and their use in pharmaceutical compositions and in treating inflammation are disclosed.

L5 ANSWER 62 OF 80 USPATFULL
AN 90:69866 USPATFULL
TI Leukotriene by amides and hydrazides
IN Young, Robert N., Senneville, Canada
Rokach, Joshua, Chemedey, Laval, Canada
Hayes, Edward C., Lincroft, NJ, United States
PA Merck Frosst Canada, Inc., Kirkland, Canada (non-U.S. corporation)
Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 4954638 19900904
AI US 1988-227038 19880801 (7)
RLI Division of Ser. No. US 1986-859971, filed on 5 May 1986, now patented, Pat. No. US 4767745 which is a continuation of Ser. No. US 1984-665596, filed on 29 Oct 1984, now abandoned which is a continuation-in-part of Ser. No. US 1983-565263, filed on 17 Dec 1983, now abandoned which is a continuation-in-part of Ser. No. US 1982-370229, filed on 20 Apr 1982, now abandoned And a continuation-in-part of Ser. No. US 1983-560663, filed on 12 Dec 1983, now abandoned
DT Utility
EXNAM Primary Examiner: Phillips, Delbert R.; Assistant Examiner: Perkins, Susan M.
LREP Lopez, Gabriel; Pfeiffer, Hesna J.
CLMN Number of Claims: 4
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 677
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Leukotrienes may be conjugated with various proteins such as Bovine Serum Albumin (BSA) and Hemocyanin from Giant Keyhole Limpets (KLH) using 1,5-difluoro-2,4-dinitrobenzene or 6-N-maleimidohexanoic acid chloride as coupling agents.

These conjugates are useful as reagents in a newly developed immunoassay for leukotrienes, as well as having potential utility as chemical immunotherapeutic agents in the treatment of various allergic and chronic inflammatory diseases of the skin, lung, and airways, including asthma, allergic rhinitis, **rheumatoid arthritis**, and skin diseases such as psoriasis and eczema.

L5 ANSWER 63 OF 80 USPATFULL
AN 90:21543 USPATFULL
TI Peptide derivatives
IN Bergeson, Scott H., Wilmington, DE, United States
PA ICI Americas Inc., Wilmington, DE, United States (U.S. corporation)
PI US 4910190 19900320
AI US 1987-5538 19870120 (7)
RLI Continuation-in-part of Ser. No. US 1986-821150, filed on 21 Jan 1986, now abandoned
PRAI GB 1985-1522 19850122
GB 1985-1523 19850122
GB 1985-1524 19850122
DT Utility
EXNAM Primary Examiner: Phillips, Delbert R.
LREP Miano, Rosemary M.; Jackson, Thomas E.
CLMN Number of Claims: 9
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 5524
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention concerns pharmaceutically useful trifluoromethyl ketone substituted di-, tri- and tetra-peptide derivatives of the formulae Ia, Ib, Ic set out hereinafter, and salts thereof, which are inhibitors of human leukocyte elastase. Also described herein are pharmaceutical compositions containing a peptide derivative and processes and intermediates for use in the manufacture of the peptide derivatives.

L5 ANSWER 64 OF 80 USPATFULL
AN 90:7700 USPATFULL
TI Lipoxygenase inhibiting compounds
IN Summers, Jr., James B., Libertyville, IL, United States
PA Abbott Laboratories, Abbott Park, IL, United States (U.S. corporation)
PI US 4897422 19900130

AI US 1987-12978 19870210 (7)
DT Utility
EXNAM Primary Examiner: Evans, J. E.
LREP Stevenson, Robert W.; Weinstock, Steven F.; Crowley, Steven R.
CLMN Number of Claims: 6
ECL Exemplary Claim: 1,4
DRWN No Drawings
LN.CNT 598
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds of the formula: ##STR1## where R.sub.1 is amino or methyl; R.sub.2 is C.sub.1 -C.sub.2 alkyl; R.sub.3 is one or more substituents selected from hydrogen, halogen or trihalomethyl; R.sub.4 is one or more substituents selected from hydrogen, halogen, trihalomethyl, C.sub.1 to C.sub.4 alkoxy or C.sub.1 to C.sub.4 alkyl; and M is hydrogen, a pharmaceutically acceptable cation, aroyl, or C.sub.1 to C.sub.6 alkoyl are inhibitors of 5- and/or 12-lipoxygenase enzymes.

L5 ANSWER 65 OF 80 USPATFULL
AN 89:84272 USPATFULL
TI Indole, benzofuran, benzothiophene containing lipoxygenase inhibiting compounds
IN Summers, Jr., James B., Libertyville, IL, United States
Gunn, Bruce P., Island Lake, IL, United States
Brooks, Dee W., Libertyville, IL, United States
PA Abbott Laboratories, Abbott Park, IL, United States (U.S. corporation)
PI US 4873259 19891010
AI US 1988-138073 19880111 (7)
RLI Continuation-in-part of Ser. No. US 1987-60784, filed on 10 Jun 1987, now abandoned which is a continuation-in-part of Ser. No. US 1987-12970, filed on 10 Feb 1987, now abandoned
DT Utility
EXNAM Primary Examiner: Siegel, Alan
LREP Weinstock, Steven F.; Crowley, Steven R.; Katz, Martin L.
CLMN Number of Claims: 25
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1764
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds of the formula: ##STR1## wherein R.sub.1 is (1) hydrogen, (2) C.sub.1 to C.sub.4 alkyl, (3) C.sub.2 to C.sub.4 alkenyl, or (4) NR.sub.2 R.sub.3, wherein R.sub.2 and R.sub.3 are independently selected from (1) hydrogen, (2) C.sub.1 to C.sub.4 alkyl and (3) hydroxyl, but R.sub.2 and R.sub.3 are not simultaneously hydroxyl;
wherein X is oxygen, sulfur, SO.sub.2, or NR.sub.4, wherein R.sub.4 is (1) hydrogen, (2) C.sub.1 to C.sub.6 alkyl, (3) C.sub.1 to C.sub.6 alkoyl, (4) aroyl, or (5) alkylsulfonyl;
A is selected from C.sub.1 to C.sub.6 alkylene and C.sub.2 to C.sub.6 alkenylene;
n is 1-5;
Y is selected independently at each occurrence from (1) hydrogen, (2) halogen, (3) hydroxy, (4) cyano, (5) halosubstituted alkyl, (6) C.sub.1 to C.sub.12 alkyl, (7) C.sub.2 to C.sub.12 alkenyl, (8) C.sub.1 to C.sub.12 alkoxy, (9) C.sub.3 to C.sub.8 cycloalkyl, (10) C.sub.1 -C.sub.8 thioalkyl, (11) aryl, (12) aryloxy, (13) aroyl, (14) C.sub.1 to C.sub.12 arylalkyl, (15) C.sub.2 to C.sub.12 arylalkenyl, (16) C.sub.1 to C.sub.12 arylalkoxy, (17) C.sub.1 to C.sub.12 arylthioalkoxy, and substituted derivatives of (18) aryl, (19) aryloxy, (20) aroyl, (21) C.sub.1 to C.sub.12 arylalkyl, (22) C.sub.2 to C.sub.12 arylalkenyl, (23) C.sub.1 to C.sub.12 arylalkoxy, or (24) C.sub.1 to C.sub.12 arylthioalkoxy, wherein substituents are selected from halo, nitro, cyano, C.sub.1 to C.sub.12 alkyl, alkoxy, and halosubstituted alkyl;
Z is oxygen or sulfur;
and M is hydrogen, a pharmaceutically acceptable cation, aroyl, or C.sub.1 to C.sub.12 alkoyl, are potent inhibitors of 5- and/or 12-lipoxygenase enzymes.

Also disclosed are lipoxygenase inhibiting compositions and a method for inhibiting lipoxygenase activity.

L5 ANSWER 66 OF 80 USPATFULL
AN 89:34405 USPATFULL
TI 6,11-Dihydro-11-(N-substituted-4-piperidylidene)-5H-benzo(5,6)cyclohepta(1,2-B)pyridines and compositions and methods of use
IN Piwinski, John J., Parsippany, NJ, United States
Ganguly, Ashit K., Upper Montclair, NJ, United States
Green, Michael J., Skillman, NJ, United States
Villani, Frank J., Fairfield, NJ, United States
Wong, Jesse, Union, NJ, United States
PA Schering Corporation, Kenilworth, NJ, United States (U.S. corporation)
PI US 4826853 19890502
AI US 1986-925342 19861031 (6)
DT Utility
EXNAM Primary Examiner: Lee, Mary C.; Assistant Examiner: Northington, Zinna
LREP Nowak, Henry P.; Billups, Richard C.; Nelson, James R.
CLMN Number of Claims: 29
ECL Exemplary Claim: 1,21
DRWN No Drawings
LN.CNT 1413
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Derivatives of 6,11-dihydro-11-(4-piperidylidene)-5H-benzo[5,6]cyclohepta[1,2-b]pyridine, and pharmaceutically acceptable salts and solvates thereof are disclosed, which possess anti-allergic and anti-inflammatory activity. Methods for preparing and using the compounds are also described.

L5 ANSWER 67 OF 80 USPATFULL
AN 89:30123 USPATFULL
TI Benzazole lipoxygenase inhibiting compounds
IN Summers, James B., Libertyville, IL, United States
Stewart, Andrew O., Libertyville, IL, United States
PA Abbott Laboratories, Abbott Park, IL, United States (U.S. corporation)
PI US 4822809 19890418
AI US 1987-120251 19871113 (7)
DT Utility
EXNAM Primary Examiner: Schwartz, Richard A.
LREP Crowley, Steven R.; Weinstock, Steven F.; Katz, Martin L.
CLMN Number of Claims: 12
ECL Exemplary Claim: 1,11
DRWN No Drawings
LN.CNT 648
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds of the formula: ##STR1## wherein R.sub.1 is (1) hydrogen, (2) C.sub.1 to C.sub.4 alkyl, (3) C.sub.2 to C.sub.4 alkenyl, or (4) NR.sub.2 R.sub.3, wherein R.sub.2 and R.sub.3 are independently selected from (1) hydrogen, (2) C.sub.1 to C.sub.4 alkyl and (3) hydroxyl, but R.sub.2 and R.sub.3 are not simultaneously hydroxyl;

X is (1) oxygen, (2) sulfur, (3) SO.sub.2, or (4) NR.sub.4, wherein R.sub.4 is (1) hydrogen, (2) C.sub.1 to C.sub.6 alkyl, (3) C.sub.1 to C.sub.6 alkyl or (4) aroyl;

A is selected from C.sub.1 to C.sub.6 alkylene and C.sub.2 to C.sub.6 alkenylene; n is 0-4;

Y is selected independently at each occurrence from (1) hydrogen, (2) halogen, (3) hydroxy, (4) cyano, (5) halosubstituted alkyl, (6) C.sub.1 to C.sub.12 alkyl, (7) C.sub.2 to C.sub.12 alkenyl, (8) C.sub.1 to C.sub.12 alkoxy, (9) C.sub.3 to C.sub.8 cycloalkyl, (10) aryl, (11) aryloxy, (12) aroyl, (13) C.sub.1 to C.sub.12 arylalkyl, (14) C.sub.2 to C.sub.12 arylalkenyl, (15) C.sub.1 to C.sub.12 arylalkoxy, (16) C.sub.1 to C.sub.12 arylthioalkoxy, and substituted derivatives of (17) aryl, (18) aryloxy, (19) aroyl, (20) C.sub.1 to C.sub.12 arylalkyl, (21) C.sub.2 to C.sub.12 arylalkenyl, (22) C.sub.1 to C.sub.12 arylalkoxy, or (23) C.sub.1 to C.sub.12 arylthioalkoxy, wherein substituents are selected from halo, nitro, cyano, C.sub.1 to C.sub.12 alkyl, alkoxy, and halosubstituted alkyl;

and M is hydrogen, a pharmaceutically acceptable cation, aroyl, or C.sub.1 to C.sub.12 alkoyl, are potent inhibitors of 5- and/or 12-lipoxygenase enzymes. Also disclosed are lipoxygenase inhibiting compositions and a method for inhibiting lipoxygenase.

L5 ANSWER 68 OF 80 USPATFULL
AN 88:57307 USPATFULL
TI Dibenzofuran lipoxygenase inhibiting compounds, compositions and use
IN Summers, James B., Libertyville, IL, United States
Moore, Jimmie L., Gurnee, IL, United States
PA Abbott Laboratories, Abbott Park, IL, United States (U.S. corporation)
PI US 4769387 19880906
AI US 1987-120301 19871113 (7)
DT Utility
EXNAM Primary Examiner: Ramsuer, Robert W.
LREP Crowley, Steven R.; Weinstock, Steven F.; Katz, Martin L.
CLMN Number of Claims: 9
ECL Exemplary Claim: 1,9
DRWN No Drawings

LN.CNT 691
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds of the formula: ##STR1## wherein R.sub.1 is (1) hydrogen, (2) C.sub.1 to C.sub.4 alkyl, (3) C.sub.2 to C.sub.4 alkenyl, or (4) NR.sub.2 R.sub.3, wherein R.sub.2 and R.sub.3 are independently selected from hydrogen, C.sub.1 to C.sub.4 alkyl and hydroxyl, but R.sub.2 and R.sub.3 are not simultaneously hydroxyl;

X is (1) oxygen, (2) sulfur, (3) SO.sub.2, or (4) NR.sub.4, wherein R.sub.4 is (1) hydrogen, (2) C.sub.1 to C.sub.6 alkyl, (3) C.sub.1 to C.sub.6 alkoyl or (4) aroyl;

A is selected from C.sub.1 to C.sub.6 alkylene and C.sub.2 to C.sub.6 alkenylene;

n is 0-4;

Y is selected independently at each occurrence from (1) hydrogen, (2) halogen, (3) hydroxy, (4) cyano, (5) halosubstituted alkyl, (6) C.sub.1 to C.sub.12 alkyl, (7) C.sub.2 to C.sub.12 alkenyl, (8) C.sub.1 to C.sub.12 alkoxy, (9) C.sub.3 to C.sub.8 cycloalkyl, (10) aryl, (11) aryloxy, (12) aroyl, (13) C.sub.1 to C.sub.12 arylalkyl, (14) C.sub.2 to C.sub.12 arylalkenyl, (15) C.sub.1 to C.sub.12 arylalkoxy, (16) C.sub.1 to C.sub.12 arylthioalkoxy, and substituted derivatives fo (17) aryl, (18) aryloxy, (19) aroyl, (20) C.sub.1 to C.sub.12 arylalkyl, (21) C.sub.2 to C.sub.12 arylalkenyl, (22) C.sub.1 to C.sub.12 arylalkoxy, or (23) C.sub.1 to C.sub.12 arylthioalkoxy, wherein substituents are selected from halo, nitro, cyano, C.sub.1 to C.sub.12 alkyl, alkoxy, and halosubstituted alkyl;

and M is hydrogen, a pharmaceutically acceptable cation, aroyl, or C.sub.1 to C.sub.12, alkoyl are potent inhibitors of 5- and/or 12-lipoxygenase enzymes. Also disclosed are lipoxygenase inhibiting compositions and a method of inhibiting lipoxygenase.

L5 ANSWER 69 OF 80 USPATFULL
AN 88:55539 USPATFULL
TI Conjugates of leukotrienes with proteins
IN Young, Robert N., Senneville, Canada
Rokach, Joshua, Chomedey-Laval, Canada
Hayes, Edward C., Lincroft, NJ, United States
PA Merck Frosst Canada, Inc., Kirkland, Canada (non-U.S. corporation)
Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 4767745 19880830
AI US 1986-859971 19860505 (6)
RLI Continuation of Ser. No. US 1984-665596, filed on 29 Oct 1984, now abandoned which is a continuation-in-part of Ser. No. US 1983-565263, filed on 17 Dec 1983, now abandoned which is a continuation-in-part of Ser. No. US 1982-370229, filed on 20 Apr 1982, now abandoned And a continuation-in-part of Ser. No. US 1983-560663, filed on 12 Dec 1983, now abandoned
DT Utility
EXNAM Primary Examiner: Phillips, Delbert R.
LREP Lopez, Gabriel; Pfeiffer, Hesna J.
CLMN Number of Claims: 8
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 701
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Leukotrienes may be conjugated with various proteins such as Bovine Serum Albumin (BSA) and Hemocyanin from Giant Keyhole Limpets (KLH) using 1,5-difluoro-2,4-dinitrobenzene or 6-N-maleimidohexanoic acid chloride as coupling agents.

These conjugates are useful as reagents in a newly developed immunoassay for leukotrienes, as well as having potential utility as chemical immunotherapeutic agents in the treatment of various allergic and chronic inflammatory diseases of the skin, lung, and airways, including asthma, allergic rhinitis, **rheumatoid arthritis**, and skin diseases such as psoriasis and eczema.

L5 ANSWER 70 OF 80 USPATFULL
AN 87:4879 USPATFULL
TI Substituted cephalosporins as anti-inflammatory and antidegenerative agents
IN Doherty, James B., New Milford, NJ, United States
Finke, Paul E., Metuchen, NJ, United States
Firestone, Raymond A., Fanwood, NJ, United States
Shah, Shrenik S., Clark, NJ, United States
Thompson, Kevan R., Westfield, NJ, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 4637999 19870120
AI US 1983-490617 19830502 (6)
DT Utility
EXNAM Primary Examiner: Rizzo, Nicholas S.
LREP Cheng, Theresa Y.; Sudol, Michael C.
CLMN Number of Claims: 8
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1550
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Substituted cephalosporins are found to be potent elastase inhibitors and thereby useful antiinflammatory/antidegenerative agents.

L5 ANSWER 71 OF 80 USPATFULL
AN 85:61082 USPATFULL
TI Conformationally restricted thymopentin-like compounds
IN Goldstein, Gideon, Short Hills, NJ, United States
Heavner, George, Flemington, NJ, United States
Audhya, Tapan, Bridgewater, NJ, United States
Tjoeng, Foe-Siong, Neshanic Station, NJ, United States
PA Ortho Pharmaceutical Corporation, Raritan, NJ, United States (U.S. corporation)
PI US 4547489 19851015
AI US 1984-618968 19840611 (6)
DT Utility
EXNAM Primary Examiner: Phillips, Delbert R.
LREP Dellenbaugh, Geoffrey G.
CLMN Number of Claims: 9
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1092
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Immunoregulating peptides are disclosed which are cyclic peptides similar to thymopentin. These peptides are useful for their effects on the immune system, especially the treatment of thymic deficiencies.

L5 ANSWER 72 OF 80 USPATFULL
AN 85:4928 USPATFULL
TI Pyridyl-substituted-benzofurans
IN Johnson, Roy A., Norfolk County, MA, United States
PA The Upjohn Company, Kalamazoo, MI, United States (U.S. corporation)
PI US 4495357 19850122
AI US 1982-430306 19820930 (6)
RLI Continuation-in-part of Ser. No. US 1982-385622, filed on 8 Jun 1982, now abandoned which is a continuation-in-part of Ser. No. US 1981-279374, filed on 1 Jul 1981, now abandoned
DT Utility
EXNAM Primary Examiner: Rotman, Alan L.; Assistant Examiner: Dentz, Bernard I.
LREP Welch, Lawrence T.
CLMN Number of Claims: 33
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1943
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides novel pyridinyl-benzofurans and derivatives thereof which are useful as thromboxane A.sub.2 (TXA.sub.2) synthetase inhibitors and as such represent potent pharmacological agents.

L5 ANSWER 73 OF 80 USPATFULL
AN 81:34511 USPATFULL
TI Modulating the immune response with 2-substituted-3-hydroxythiazolo[2,3-b]be
IN Wei, Peter H. L., Springfield, PA, United States
Gregory, Francis J., Berwyn, PA, United States
PA American Home Products Corporation, New York, NY, United States (U.S. corporation)
PI US 4275065 19810623
AI US 1980-130483 19800331 (6)
RLI Continuation-in-part of Ser. No. US 1979-50847, filed on 21 Jun 1979, now abandoned
DT Utility
EXNAM Primary Examiner: Schwartz, Richard A.
LREP Tarnowski, George

CLMN Number of Claims: 18
ECL Exemplary Claim: 18
DRWN No Drawings
LN.CNT 847
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Novel 2-substituted-3-hydroxythiazolo[2,3-b]benzo-(and azabenzo)thiazolium salts, the mesoionic didehydro derivatives thereof and related compounds are disclosed, as well as the use thereof as modulators of the immune response.

L5 ANSWER 74 OF 80 USPATFULL
AN 80:65783 USPATFULL
TI Bradykinin-inhibiting tripeptide derivatives
IN Claeson, Karl G., Lidingo, Sweden
Simonsson, Leif R., Hisings-Backa, Sweden
Arielly, Salo, Kungsbacka, Sweden
PA AB Kabi, Stockholm, Sweden (non-U.S. corporation)
PI US 4242329 19801230
AI US 1979-58333 19790717 (6)
PRAI SE 1978-7937 19780718
DT Utility
EXNAM Primary Examiner: Phillips, Delbert R.
LREP Pollock, Vande Sande & Priddy
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 491
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Tripeptide derivatives of the formula
H-D-X-Phe-Arg-Y
in which
X is selected from the group consisting of Pro and Phe
Y is selected from the group consisting of O--R.sub.1 and NH--R.sub.2 inwhich R.sub.1 is selected from the group consisting of straight, branched and cyclic alkyl group with 1-12 C atoms, and
R.sub.2 is selected from the group consisting of H, straight, branched and cyclic alkyl group with 1-12 C atoms, and physiologically acceptablesalts thereof.
A process for producing said tripeptide derivatives by synthesis and purification methods which are known in the peptide chemistry.
harmaceutical preparations comprising said tripeptide derivatives.

L5 ANSWER 75 OF 80 USPATFULL
AN 78:43916 USPATFULL
TI 1,3-Benzodithiolanes
IN Sprague, Peter W., Titusville, NJ, United States
Heikes, James E., East Windsor, NJ, United States
PA E. R. Squibb & Sons, Inc., Princeton, NJ, United States (U.S. corporation)
PI US 4107175 19780815
AI US 1976-751552 19761217 (5)
RLI Division of Ser. No. US 1976-705849, filed on 16 Jul 1976, now Defensive Publication No.
DT Utility
EXNAM Primary Examiner: Jaisle, Cecilia M.
LREP Levinson, Lawrence S.; Smith, Merle J.; Barrack, Donald J.
CLMN Number of Claims: 21
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1227
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds having the formula ##STR1## and the pharmaceutically acceptable salts thereof, wherein R.sub.1 is hydrogen, halogen, trifluoromethyl, alkyl, alkoxy, nitro, amino, or hydroxy; R.sub.2 is carboxyl or alkoxycarbonyl; and n is 0, 1, 2, 3, 4 or 5; have antiinflammatory activity.

L5 ANSWER 76 OF 80 USPATFULL
AN 78:40990 USPATFULL
TI 1,3-Benzodithiolanes
IN Sprague, Peter W., Titusville, NJ, United States
Heikes, James E., East Windsor, NJ, United States
PA E. R. Squibb & Sons, Inc., Princeton, NJ, United States (U.S. corporation)
PI US 4104467 19780801
AI US 1976-705849 19760716 (5)
DT Utility
EXNAM Primary Examiner: Coughlan, Jr., Paul M.
LREP Levinson, Lawrence S.; Smith, Merle J.; Barrack, Donald J.
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1253
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds having the formula ##STR1## and the pharmaceutically acceptable salts thereof, wherein R.sub.1 is hydrogen, halogen, trifluoromethyl, alkyl, alkoxy, nitro, amino, or hydroxy; and R.sub.2 is an amino group, a 5- or 6-membered heterocyclic group, a 3-indolyl group, carboxyl, or alkoxycarbonyl; and n is 0, 1, 2, 3, 4 or 5; have antiinflammatory activity.

L5 ANSWER 77 OF 80 USPATFULL
AN 77:22467 USPATFULL
TI 9-Deoxy-9.alpha.-hydroxymethyl-PGF.sub.2 analogs
IN Bundy, Gordon L., Kalamazoo, MI, United States
PA The Upjohn Company, Kalamazoo, MI, United States (U.S. corporation)
PI US 4021467 19770503
AI US 1976-651622 19760123 (5)
RLI Division of Ser. No. US 1975-556768, filed on 10 Mar 1975, now patented, Pat. No. US 3950363
DT Utility
EXNAM Primary Examiner: Gerstl, Robert
LREP Spaeth, Earl C.; Armitage, Robert A.
CLMN Number of Claims: 10
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2126
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The disclosure includes novel cyclic ethers of the formulas: ##STR1## In these formulas, X and Y are --O-- or a valence bond with the proviso that one of X and Y is --O-- and the other is a valence bond; R is hydrogen, alkyl of one to 4 carbon atoms; inclusive, or a pharmacologically acceptable cation; R.sub.2 and R.sub.3 are hydrogen, methyl, or ethyl; and A is ##STR2## wherein R.sub.4 is hydrogen, methyl, or ethyl with the proviso that R.sub.2 and R.sub.3 are both hydrogen when R.sub.4 is methyl or ethyl. The compounds of the first of these formulas are useful as vasoconstrictors and enhancers of platelet aggregation, and are useful in the control of bleeding in mammals, including man. The compounds of the second of these formulas are useful in the treatment of inflammation.

L5 ANSWER 78 OF 80 USPATFULL
AN 76:20185 USPATFULL
TI Prostaglandin cyclic ethers
IN Bundy, Gordon L., Kalamazoo, MI, United States
PA The Upjohn Company, Kalamazoo, MI, United States (U.S. corporation)
PI US 3950363 19760413
AI US 1975-556768 19750310 (5)
DT Utility
EXNAM Primary Examiner: Jiles, Henry R.; Assistant Examiner: Dentz, Bernard I.
LREP Spaeth, Earl C.
CLMN Number of Claims: 25
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2118
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The disclosure includes novel cyclic ethers of the formulas: ##SPC1##

In these formulas, X and Y are --O-- or a valence bond with the proviso that one of X and Y is --O-- and the other is a valence bond; R is hydrogen, alkyl of one to 4 carbon atoms, inclusive, or a pharmacologically acceptable cation; R.sub.2 and R.sub.3 are hydrogen, methyl, or ethyl; and A is ##EQU1## wherein R.sub.4 is hydrogen, methyl, or ethyl with the proviso that R.sub.2 and R.sub.3 are both hydrogen when R.sub.4 is methyl or ethyl. The compounds of the first of these formulas are useful as vasoconstrictors and enhancers of platelet aggregation, and are useful in the control of bleeding in mammals, including man. The compounds of the second of these formulas are useful in the treatment of inflammation.

L5 ANSWER 79 OF 80 USPATFULL
AN 75:52723 USPATFULL
TI Isoindolo [7,1,2-hij]quinolines
IN Levine, Seymour D., North Brunswick, NJ, United States
PA E. R. Squibb & Sons, Inc., Princeton, NJ, United States (U.S. corporation)

PI US 3910926 19751007
AI US 1973-417157 19731119 (5)
RLI Division of Ser. No. US 1972-215189, filed on 3 Jan 1972, now patented, Pat. No. US 3819624, issued on 25 Jun 1974
DT Utility
EXNAM Primary Examiner: Daus, Donald G.; Assistant Examiner: Wheeler, David E.
LREP Levinson, Lawrence S.; Smith, Merle J.; Barrack, Donald J.
CLMN Number of Claims: 8
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 798
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Isoindolo[7,1,2-hij]quinolines are provided having the structure ##SPC1##

Wherein R.sup.5 can be hydroxyl, halogen, substituted amino, alkoxy, acyloxy, aroyloxy, substituted amido, and amino-subsituted amido; and R.sup.6 is hydrogen; and R.sup.5 and R.sup.6 can be taken together to form =O; X, Y, R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are as defined below; and which are anti-inflammatory agents, central nervous system depressants, inhibitors of cyclic AMP phosphodiesterase and sun-screening agents.

L5 ANSWER 80 OF 80 USPATFULL
AN 74:45598 USPATFULL
TI PREPARATION OF NOVEL DERIVATIVES OF 2,3 DIHYDROXYPROPYL-N-(7 OR 8 CHLORO-4 QUINOLINYL)ANTHRANILATE
IN Theriault, Robert John, Kenosha, WI, United States
Karwowski, James Paul, Mundelein, IL, United States
Wideburg, Norman Earl, Waukegan, IL, United States
PA Abbott Laboratories, Chicago, IL, United States (U.S. corporation)
PI US 3839152 19741001
AI US 1973-359141 19730510 (5)
RLI Division of Ser. No. US 1971-190690, filed on 19 Oct 1971, now patented, Pat. No. US 3790578
DT Utility
EXNAM Primary Examiner: Tanenholtz, Alvin E.
LREP Niblack, Robert L.; Krei, Joyce R.; Mallare, Vincent A.
CLMN Number of Claims: 1
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 171
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A process of preparing novel derivatives of 2,3-dihydroxypropyl-N-(7 or 8-chloro-4-quinolinyl)anthranilate. The compounds are represented by the formula ##SPC1##

Wherein the chloro is in the 7- or 8-position and R is --CH.sub.2 OCH.sub.3. The compounds are prepared by microbial transformation of 2,3-dihydroxypropyl-N-(7 or 8-chloro-4-quinolinyl)anthranilate. The compounds are useful as analgesic and anti-inflammatory agents.

=> log h

COST IN U.S. DOLLARS	ENTRY	SINCE FILE SESSION	TOTAL
FULL ESTIMATED COST		124.75	200.36

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	ENTRY	SINCE FILE SESSION	TOTAL
CA SUBSCRIBER PRICE		0.00	-0.56

SESSION WILL BE HELD FOR 60 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 10:10:50 ON 30 MAR 2000

L5 ANSWER 17 OF 80 USPATFULL
AN 1998:156821 USPATFULL
TI Composition containing peptides and nucleic acids and methods of making same
IN Kochel, Bonawentura, Wroclaw, Poland
PA Immune Modulation Maximum, New York, NY, United States (U.S. corporation)
PI US 5849196 19981215
AI US 1996-726650 19961007 (8)
DT Utility
EXNAM Primary Examiner: Elliott, George C.; Assistant Examiner: Larson, Thomas G.
LREP Carrier, Blackman & Associates, P.C.; Carrier, Joseph P.; Esser, William F.
CLMN Number of Claims: 16
ECL Exemplary Claim: 9
DRWN 6 Drawing Figure(s); 3 Drawing Page(s)
LN.CNT 946
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB An improved composition containing peptides and nucleic acids has active components, i.e., which heighten the phagocytic activity f neutrophils, consisting of molecules with a molecular weight of at least 8 kDa, and preferably at least 15 kDa. The active components comprise peptides without aromatic portions and will absorb light at an absorption band of .DELTA..lambda.=200-235 mn, .lambda..sub.max =205 nm, in the UV spectrum. The composition is nontoxic and is formulated using casein, blood albumin, beef peptone, nucleic acid (RNA) and a base such as sodium hydroxide. The composition stimulates phagocytic activity of neutrophils if used at sufficient concentrations. A separate composition is obtained using the same components of manufacture, but filtering or centrifuging the composition to a molecular weight of <8-15 kDa which inhibits phagocytic activity of neutrophils for application in treating auto immune diseases.

L3 ANSWER 17 OF 35 PROMT COPYRIGHT 2000 Gale Group

AN 1998:149751 PROMT
TI Advanced Viral Research Corp. Announces Extension of Research Agreement with National Cancer Institute
SO PR Newswire, (24 Mar 1998) pp. 0324NYTU003.
LA English
WC 325
FULL TEXT IS AVAILABLE IN THE ALL FORMAT
AB YONKERS, N.Y., March 24 /PRNewswire/ -- Advanced Viral Research Corp. (OTC Bulletin Board: ADVR) today announced that its Materials Transfer Agreement-Cooperative Research and Development Agreement (MTA-CRADA) with the National Cancer Institute (NCI) for research with ADVR's flagship drug, **Reticulose**, has been extended for one year, beginning March 4, 1998 and ending March 3, 1999.

Reticulose is a non-toxic immunomodulator that has been shown to have a broad spectrum of antiviral therapeutic effects in patients. At the NCI, **Reticulose** is being used to study the basic mechanisms of immune responses. This scientific research is led by Dr. Howard Young, Section Chief in the Laboratory of Experimental Immunology at the NCI, an expert on interferon-gamma. Using kidney tumor model systems, Dr. Young is investigating the anti-tumor activity of **Reticulose**. In addition, Dr. Young and his colleagues will study the effects of **Reticulose** on inflammation associated with **rheumatoid** arthritis.

"The extension of this collaborative agreement between Advanced Viral Research Corp. and one of the premier immunology research laboratories is an important event. We expect these research efforts to provide new insights into the therapeutic potentials, and uses of **Reticulose** while adding to our basic understanding of the workings of the immune system," stated Dr. Shalom Z. Hirschman, President and Chief Executive Officer of Advanced Viral Research Corp.

This news release contains forward-looking statements that involve risks and uncertainties, including risks associated with clinical development, regulatory approvals, including application to the FDA, product commercialization and other risks described from time to time in the SEC reports filed by ADVR. **Reticulose** is not approved by the U.S. Food and Drug Administration or any comparable agencies of any other countries.

National Library of Medicine: IGM Results Screen

Citations 1 to 5 of 5 from MEDLINE

☐ **TITLE:** Peptide nucleic acids stimulate gamma interferon and inhibit the replication of the human immunodeficiency virus.

Full Citation **AUTHORS:** Hirschman SZ, Chen CW

SOURCE: J Investig Med. 1996 Aug;44(6):347-51.

Related Articles **CIT. IDS:** PMID: 8795297 UI: 96387866

☐ **TITLE:** The efficacy of a peptide-nucleic acid solution (Reticulose) for the treatment of hepatitis A and hepatitis B--a preliminary controlled human clinical trial.

Full Citation **AUTHORS:** Cohen M

SOURCE: J R Soc Health. 1992 Dec;112(6):266-70.

Related Articles **CIT. IDS:** PMID: 1469671 UI: 93108371

☐ **TITLE:** In vitro antiviral activity of a peptide-nucleic acid solution against the human immunodeficiency virus and influenza A virus.

Full Citation **AUTHORS:** Friedland B

SOURCE: J R Soc Health. 1991 Oct;111(5):170-1.

Related Articles **CIT. IDS:** PMID: 1724467 UI: 92177329

☐ **TITLE:** Ultrastructural and ultrahistochemical studies on the ventral aorta in larvae of a teleost, Poecilia reticulata.

Full Citation

AUTHORS: Leknes IL

SOURCE: Anat Anz. 1986;161(1):43-51.

Related Articles **CIT. IDS:** PMID: 3010778 UI: 86213134

☐ **TITLE:** [Reticular hyperplasia of the skin caused by light. Actino-reticulose, actinic-reticuloid].

Full Citation

AUTHORS: Korting GW

SOURCE: Med Welt. 1971 May 15;20:826-7. German. No abstract available.

Related Articles **CIT. IDS:** PMID: 4252502 UI: 71186953

National Library of Medicine: IGM Full Record Screen

Related Articles

TITLE:	Peptide nucleic acids stimulate gamma interferon and inhibit the replication of the human immunodeficiency virus.
AUTHORS:	Hirschman SZ; Chen CW
AUTHOR AFFILIATION:	Department of Medicine, Mount Sinai School of Medicine, New York, NY 10029, USA.
SOURCE:	J Investig Med 1996 Aug;44(6):347-51
CITATION IDS:	PMID: 8795297 UI: 96387866
ABSTRACT:	BACKGROUND: Peptide nucleic acids (PNAs) are newly appreciated molecules consisting of both amino acids and nucleotides that already have been shown to have interesting properties; for example, they are very stable and have antisense activity. Reticulose, a peptide nucleic acid preparation that had been used for many years to treat human viral infections such as influenza, was investigated for inhibitory effects on the replication of the human immunodeficiency virus (HIV) in cell culture systems. METHODS: H9 and peripheral blood mononuclear cells (PBMCs) were treated with reticulose before, during, and after infection with HIV-1 at various multiplicities. Treatment of cells with PNA significantly inhibited replication of HIV-1 as measured by synthesis of viral mRNA and p24 protein, reverse transcriptase activity, and syncitial cell formation. Exposure of cells to PNA under conditions that favor transfection of DNA, such as electroporation, markedly enhanced the

	inhibition of HIV replication. RESULTS: In experiments to examine the mechanism of inhibition, it was found that PNA stimulated production of a distinctive cassette of chemokine mRNAs in PBMC cultures. Cytokines stimulated by reticulose included gamma interferon, interleukin-6, interleukin-1, and tissue necrosis factor-alpha. CONCLUSIONS: These results offer new tools for the study of immune functions and, moreover, open new approaches to the therapy of HIV infection and AIDS.
MAIN MESH HEADINGS:	**Antiviral Agents/*pharmacology HIV-1/*physiology Interferon Type II/*biosynthesis Nucleic Acids/*pharmacology Peptides/*pharmacology**
ADDITIONAL MESH HEADINGS:	**Chemokines/genetics Human HIV-1/drug effects Interferon Type II/genetics RNA, Messenger/biosynthesis Support, Non-U.S. Gov't Tumor Cells, Cultured Virus Replication/drug effects 1996/08 1996/01 00:00**
PUBLICATION TYPES:	**JOURNAL ARTICLE**
CAS REGISTRY NUMBERS:	**0 (reticulose) 0 (Antiviral Agents) 0 (Chemokines) 0 (Nucleic Acids) 0 (Peptides) 0 (RNA, Messenger) 82115-62-6 (Interferon Type II)**
LANGUAGES:	**Eng**

Order Documents | Log off IGM
Next Record | Details Of Search | Return to Results | Return to Search Screen | Previous Record